Die sensationelle GenoMed (GMED) Story! - 500 Beiträge pro Seite

[morchel]

....über DNAP bin ich auf GMED gestoßen!

GenoMed Inc. (Pinksheets:GMED) ist ein Startup Unternehmen in der Genforschung!
lt. Craig Hall, der auch seinerzeit die Investorrealations für DNAP gemanagt hat wird das Filing das für das Listing an der OTCBB notwendig ist Ende Jänner eingericht!

Alle News
http://www.newsalert.com/bin/digest?Symbol=GMED#news
Webseite
http://www.genomedics.com

Momentan ist GMED dabei sein Scientific Advisory Board (Wissenschaftliche Berater) zu vergrößern und hat Verträge mit Firmen geschlossen die ihnen Die gewünschten Gewebsproben für ihre Forschingen liefern werden!
Diese Firma ist so interessant in ihren Forschungen das ich ihnen demnächst einen umfassenden Bericht auf meiner Seite (http://www.zockstocks.com) widmen werde! Newsletterbezieher bekommen ihn natürlich frei Haus!

morchel
http://www.zockstocks.com

[DNAPSPAZ]

Weder WKN,noch ISIN zu finden - genau wie bei NOGN.

Fazit:in D nicht zu ordern

Croko

[cariocca]

GMED

CH: 1311690
US: 37243C1027
GB:2808398

No Germany...

Kommt doch in die Schweiz, da könnt ihr ALLES ordern.


Gruss

Roger

[liebemachtblind]

Ich liebe die SCHWEIZ
COOLES VOLK
Gruß
ANDY

[cariocca]

Danke, liebemachtblind

Cari-Jololodi-occa

[Bombenleger]

GenoMed, Inc. Finalizes Letter of Agreement With Muna, Inc. to Obtain DNA Specimens for the
Study of Diseases Within the Hispanic Population

ST. LOUIS, Jan. 25 /PRNewswire-FirstCall/ -- GenoMed Inc. ("the Company" or "GenoMed") (OTC Pink Sheets:
GMED), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that GenoMed has
entered into a Letter of Agreement with Muna, Inc., a Florida company, to obtain blood samples from Hispanic patients
with a variety of common diseases.

Dr. Leo A. Gosser, Ph.D., CEO of Muna, Inc., has established a substantial network of physicians in southern Florida to
assist in the collection of blood samples within the Hispanic and other populations. GenoMed will assist Muna, Inc. in
establishing a computer database for the collection of clinical information specific to each patient sample. The samples will
be made anonymous as soon as feasibly possible during the collection process.

David Moskowitz, Chief Medical Officer of GenoMed, stated, "We are pleased to be working with Dr. Gosser and Muna,
Inc. to obtain these samples. The incidence of type 2 diabetes and its complications are especially high within the Hispanic
community. Each ethnic group must be screened for its own specific set of disease-causing genes, since the genes vary
according to ethnic group." Dr. Moskowitz added, "To leave any one group out would be to delay optimal healthcare for
that group. Our intention is to encompass each of the human populations without prejudice in our search for disease genes."

Dr. Leo Gosser states, "We are pleased to establish this relationship with GenoMed, and to be on the cutting edge of
genotyping research."

About GenoMed

GenoMed was founded with the sole purpose of translating knowledge of disease genomics into improved patient
treatments. The Company is screening millions of genotypes for association with various diseases in an effort to identify
novel therapeutic targets for existing prescription drugs. GenoMed expects to generate revenues by licensing disease gene
research data to the pharmaceutical industry to serve as targets for new drugs, and to clinical diagnostic laboratories for the
early diagnosis of disease. The Company has filed initial patent applications with the United States Patent and Trademark
Office that document improved patient outcomes in pilot trials.

For additional information please visit www.genomedics.com and/or contact Craig Hall at [phone] or email at
[e-mail].

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the beneficial nature of
the share exchange. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will
continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those
projected in the forward-looking statements as a result of a number of risks and uncertainties. Among other things,
competition from existing or new competitors will impact our business; our research and development is subject to
economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press
release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not
undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X55915513

SOURCE GenoMed, Inc.

CONTACT: Craig Hall of Research Capital, [phone], or
[e-mail], for GenoMed, Inc.

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Announces Purchase of Beta Version of SNPstream Ultra High Throughput
Genotyping System

ST. LOUIS, Jan 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed") a St. Louis, Missouri-based medical genomics biotechnology company, today announced that it
has purchased a beta version of the SNPstream UHT genotyping system from Orchid BioSciences for industrial-scale
single nucleotide polymorphism (SNP) scoring. GenoMed, Inc. intends to score a minimum of four million (4,000,000)
genotypes annually using the SNPstream UHT platform and SNPware(TM) kits incorporating Orchid`s proprietary
SNP-IT(TM) primer extension biochemistries and software.

Under the beta purchase agreement, GenoMed, Inc. will provide pertinent data to Orchid specific to the performance and
operation of the SNPstream UHT genotyping system. Additional details of the agreement were not disclosed.

GenoMed will use the SNPstream UHT system to initially genotype diabetes samples at thousands of SNPs. GenoMed is
using this large number of SNPs, version 1.0 of its Disease GeneNet(TM), to find SNPs and genes associated with type 2
diabetes. GenoMed will also use the SNPstream UHT system for genotyping of other diseases, including, but not limited
to, complications of diabetes such as kidney failure, neuropathy, stroke and heart attacks, as well as cancer of the breast,
lung, colon, and prostate."

About GenoMed

GenoMed was founded with the sole purpose of translating knowledge of disease genomics into improved patient
treatments. The Company is screening millions of genotypes for association with various diseases in an effort to identify
novel therapeutic targets for existing prescription drugs. GenoMed expects to generate revenues by licensing its discoveries
to the pharmaceutical industry for the expansion of drug labels and early diagnosis of disease. The Company has already
filed initial patent applications with the United States Patent and Trademark Office that substantiate improved patient
outcomes in pilot trials.

For additional information please visit www.genomedics.com and/or contact Craig Hall @ [phone] or email at
[e-mail] for a GenoMed investor package.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the beneficial nature of
the purchase of Orchid`s SNPstream UHT genotyping system. The words or phrases "would be," "will allow," "intends to,"
"will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number
of risks and uncertainties. Among other things, competition from existing or new competitors will impact our business; our
research and development is subject to economic, regulatory, governmental, and technological factors. Statements made
herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, the Company does not undertake, and specifically disclaims any obligation to update any
forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of
such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X07743773

SOURCE GenoMed, Inc.

CONTACT: Craig Hall of GenoMed, Inc., [phone], or
[e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Announces Drug Therapy that Delays Kidney Disease

ST. LOUIS, Feb 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today a
new drug treatment that delays the progression of kidney disease caused by type 2 diabetes (adult-onset diabetes).

Based on pilot data over three years conducted by Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical
Officer, the drug regimen slowed the rate of progression of renal disease due to type 2 diabetes by 200 percent in
African-American men and 50 percent in Caucasian men. The disease was reversed altogether when patients were treated
early in the course of the disease -- before their serum creatinine, a standard measurement of kidney function, reached 2
milligrams per deciliter.

Moskowitz gave the patients a high dose of a specific ACE inhibitor. Beginning in 1993, he discovered that ACE --
angiotensin I-converting enzyme -- is a "master" disease gene that is associated with approximately 40 common, serious
diseases such as kidney disease and other complications of type 2 diabetes, high blood pressure and its complications,
emphysema, congestive heart failure and even some psychiatric diseases and common types of cancer such as colon,
prostate, and lung. Drugs used against this enzyme are called ACE inhibitors. "We`ve identified a correlation between the
ACE gene and many common diseases," Moskowitz said. "What makes the association so powerful is our clinical
outcomes data."

With the new treatment, the time to kidney dialysis for African-American men increased from 3.3 years to an average of
9.3 years; treatment for Caucasian men extended the time to dialysis from 2.7 years to 4.0 years. The data suggests that if
this new treatment were started early enough, both African-American and Caucasian patients with diabetes would never
need dialysis.

According to an article in the New England Journal of Medicine (9/20/01), the annual cost of care for patients in the United
States with end-stage renal disease (ESRD) is more than $18 billion, and accounts for six percent of the Medicare budget.
The leading causes of ESRD are diabetes and hypertension. ESRD is a chronic, incurable condition; the 10-year survival
rate is approximately 13 percent.

Moskowitz says that using existing drugs for new clinical indications is, in many cases, the quickest and least expensive way
to improve a patient`s condition. "It usually takes 10-15 years and hundreds of millions of dollars to develop a new drug
before it meets FDA approval," Moskowitz said. "Using this new regimen with an existing ACE inhibitor can delay a
patient`s renal failure and need for dialysis. This regimen should reduce the high cost of treating ESRD."

Moskowitz, a nephrologist trained at Harvard, Oxford and Washington University in St. Louis, left a career as a staff
physician at the St. Louis VA Medical Center and assistant professor at Saint Louis University School of Medicine to start
GenoMed, a biotech genomics company. "The promise of GenoMed is to improve patients` quality of life and to save
money by identifying genes which cause disease," Moskowitz said. "We have compelling data that is immediately valuable
to patients, their physicians, and their health care payors, and offers immediate cost savings."

Dr. George Griffing, director of the division of general internal medicine at Saint Louis University School of Medicine, said,
"GenoMed`s findings offer great hope to patients with certain devastating diseases, and dramatic opportunity for cost
savings."

Type 2 diabetes is nearing epidemic proportions, due to increasing numbers of older Americans and more obesity and
sedentary lifestyles, according to the American Diabetes Association. Almost six percent of the American population has
diabetes, and type 2 diabetes accounts for 90 to 95 percent of those suffering from the disease.

"I`m excited because our initial data is so promising. The challenge now is to reach health care companies and large
employers who can capitalize on the clinical and financial outcomes for patients," Moskowitz said.

The science of genomics promises to extend and improve life by identifying genes which cause disease, and then
developing drugs to counteract the effects of these disease-causing genes.

About GenoMed

GenoMed is a biotech genomics company based in St. Louis, Missouri, that is working to translate knowledge of disease
genes into better patient outcomes as rapidly and safely as possible. The company`s primary work is genotyping disease
specimens, and GenoMed expects to complete four million genotypes in 2002. Building on its initial discoveries and
success, GenoMed is dedicated to (1) identifying additional disease-associated genes; (2) working on new treatments using
existing drugs; and, (3) developing new drugs specifically designed against disease-causing genes. GenoMed`s stock ticker
symbol is GMED.

For additional information specific to the new treatment, please visit www.genomedics.com and contact Craig Hall at
941.366.6677 or e-mail at [e-mail] for a GenoMed investor package.

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the beneficial nature of
the drug therapy that slows kidney disease. The words or phrases "would be," "will allow," "intends to," "will likely result,"
"are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results
could differ materially from those projected in the forward looking statements as a result of a number of risks and
uncertainties. Among other things, competition from existing or new competitors will impact our business; our research and
development is subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of
the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by
applicable law, we do not undertake, and specifically disclaims any obligation, to update any forward-looking statements to
reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X66433193

SOURCE GenoMed, Inc.

CONTACT: Craig Hall of GenoMed, [phone], or
[e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Alliance Expected to Create DNAPrint`s First Substantial Revenue Stream; Alliance with GenoMed
Creates New Revenue Stream and Enhanced Genotyping Capabilities

SARASOTA, Fla., Mar 6, 2002 (BUSINESS WIRE) -- DNAPrint genomics, Inc. (OTCBBNAP) announced today
that it has entered into a commercial and equity-based agreement with GenoMed, Inc. (Pink Sheets:GMED) that has
upgraded DNAPrint`s facility for the provision of genotyping services. The agreement is expected to provide DNAPrint
annual revenues in excess of $1.6 million.

Under the agreement, GenoMed has purchased a beta version of an Orchid Ultra-High Throughput (UHT) genotyping
system and has integrated it with DNAPrint`s existing Orchid 25K SNPstream platform. With the integration, DNAPrint
becomes GenoMed`s exclusive genotyping contractor. The integration establishes the first commercially licensed UHT
facility operating Orchid technology in the world, and provides DNAPrint a faster and less expensive platform for its own
research and product development. In addition, the new platform establishes DNAPrint as one of only a handful of
companies in the world capable of scoring more than 100,000 genotypes per eight-hour shift.

The initial term of the contract is two years, but it automatically renews every two years thereafter in order to sensitively
determine the price per genotype that GenoMed pays DNAPrint. The contract calls for DNAPrint to produce over 4
million genotypes for GenoMed in the first year at a cost of approximately $1.6 million. The larger scope of the agreement
establishes DNAPrint and GenoMed as long-term participants in a joint commercial genotyping venture. Third party
revenues from this venture will be shared between DNAPrint and GenoMed through undisclosed terms.

As part of the deal, DNAPrint obtained a royalty stake in future GenoMed profitability.

"This agreement is a tremendous achievement for our company and our investors," said Tony Frudakis, PhD, CEO and
CSO of DNAPrint genomics, Inc. "In addition to securing a revenue stream that we hope will be substantial and consistent,
we have acquired a more advanced genotyping platform for our research, and we have joined GenoMed`s mission to apply
medical genomics to the practice of medicine."

GenoMed`s screen of the human genome is expected to result in the identification of novel therapeutic targets for common,
complex human diseases and could help pharmaceutical companies develop new, highly specific drugs and find new uses
and indications for existing therapies.

"The integrated genotyping resources will allow GenoMed to significantly expand the pace of our search for disease gene
targets at a fraction of what it would have cost us to operate independently," said David Moskowitz, MD, Chairman of
GenoMed, Inc.

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level
mathematical and statistical modeling, programming and molecular genetics. Our quest is to become the leader in the
development of complex pharmacogenomics classifiers for a personalization of drug prescription. The Company is traded
on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please
visit http://www.dnaprint.com.

About Genomed, Inc.

GenoMed is an early stage bioinformatics company based in St. Louis, Missouri. GenoMed is traded publicly under the
stock ticker symbol GMED. GenoMed is working to apply medical genomics (the study of how genes function in the
cause, progression and treatment of disease) to the development of new treatments, the better use of existing therapies and
the creation of more accurate gene-based tests for known diseases. GenoMed creates revenue through licensing and/or
collecting royalties from drug discovery, from the optimization of existing therapies and from gene-based diagnostic tests.
For more information about GenoMed, please visit http://www.genomedics.com.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E
of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual
results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations
and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation.
DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or
any change in events, conditions, or circumstances on which any such statements are based.

CONTACT: DNAPrint genomics, Inc., Sarasota
Investor Contact: Carrie Castillo, 941/366-3400
[e-mail]
or
Media Contact: Russell LaMontagne, 212/219-0800
[e-mail]

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2002 Business Wire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Files Form 10-SB With Securities and Exchange Commission

ST. LOUIS, Mo., Apr 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED)
("the Company" or "GenoMed"), a medical genomics biotechnology company, announced today that it has voluntarily filed
a Form 10-SB with the Securities and Exchange Commission pursuant to Section 12(g) of The Securities Exchange Act of
1934 in order to be eligible to apply to have its common stock quoted on the Over-the-Counter Bulletin Board.

GenoMed is a medical genomics company that is focused on identifying disease causing genes, and using these genes to
develop clinical treatments against diseases. GenoMed has relationships with disease specimen sources such as the
American Diabetes Association, Biocollections Worldwide, Muna Inc., and others for study using GenoMed`s
DiseaseGeneNet(TM) platform. GMED plans to screen a collection of over 4,000,000 Single Nucleotide Polymorphisms
(SNPs) during the next 12 months.

GMED`s Form 10 filing highlights the Company`s business model, which has three primary potential revenue sources:

1. Drug discovery: Identifying gene targets without existing therapies and
pursuing strategic alliances with large, research-oriented
pharmaceutical companies to develop new drugs against these targets.
2. Maximizing the utility and market value of existing drugs through new
clinical indications. Existing drugs may be viable treatments for
targets GenoMed identifies. For example, GenoMed has demonstrated that
a proprietary regimen of ACE inhibitors can dramatically delay the
onset of Type-2 diabetes. New indications do not require the rigorous
FDA review process and can be approved and implemented relatively
quickly.
3. Gene-based diagnostic tests: Millions of people die each year from
disease and thousands more die from responses to drugs. GenoMed`s
diagnostics identify the genes, and their variant sequences that are
associated with disease. As such, they may represent targets for new
drugs to attack disease before symptoms ever become visible. They also
can help to determine which drugs should be prescribed to a person
based on his or her unique genetic makeup.

GenoMed will genotype disease specimens using one of the fastest systems currently available in the world, Orchid
BioScience`s SNPstream Ultra High Throughput (UHT) genotyping system. GenoMed purchased the UHT system in
February 2002, and has partnered with DNAprint Genomics, Inc. (OTC Bulletin Board: DNAP) to perform the
genotyping services.

GenoMed will use its proprietary DiseaseGeneNet(TM) to fish for disease- associated genes. The Company will focus on
a large number of genes that it believes are important in causing disease. Each gene is composed of thousands of letters,
which are limited to only C, A, G, and T. At a particular position, DNA from a patient with a particular disease and a
healthy specimen may differ by as little as one letter, for example, a C among patients with the disease versus a T among
healthy controls. The C would then be associated with the disease under study, as would the entire gene containing this
Single Nucleotide Polymorphism (SNP). Drugs directed against this gene would be expected to delay the progression of
the disease. GenoMed believes that knowledge of such associations is the key to developing treatments for all common
diseases.

GenoMed`s management has experience developing new treatments for common diseases. Dr. David Moskowitz, the
Company`s Chairman and Chief Medical Officer, developed a new drug treatment that delays the progression of kidney
disease caused by type 2 diabetes (adult-onset diabetes). Based on data from patients treated by Dr. Moskowitz over a
three year period, the drug regimen slowed the rate of progression of renal disease due to type 2 diabetes by 200 percent
in African-American men and 50 percent in Caucasian men. With the new treatment, the time to kidney dialysis for
African-American men increased from 3.3 years to an average of 9.3 years; treatment for Caucasian men extended the
time to dialysis from 2.7 years to 4.0 years. The disease was reversed altogether when patients were treated early in the
course of the disease-- before their serum creatinine, a standard measurement of kidney function, reached 2 milligrams per
deciliter. The data suggests that if this new treatment were started early enough, both African-American and Caucasian
patients with diabetes would never need dialysis. According to Dr. George Griffing, the director of the division of general
internal medicine at Saint Louis University School of Medicine, "GenoMed`s findings offer great hope to patients with
certain devastating diseases, and dramatic opportunity for cost savings."

GenoMed`s use of its proprietary DiseaseGeneNet(TM) represents a unique approach to the science of medical genomics.
Medical genomics is intended to extend and improve life by identifying genes which cause disease, allowing drugs to be
developed which counteract the effects of these disease-causing genes.

About GenoMed

GenoMed is a medical genomics company based in St. Louis, Missouri, that is working to interpret the knowledge of
disease genes to provide improved patient treatments rapidly and safely. The company`s primary work is genotyping
disease specimens. Building on its initial discoveries and successes, GenoMed is dedicated to (1) identifying additional
disease- associated genes; (2) working on new treatments using existing drugs; and, (3) developing new drugs specifically
designed against disease-causing genes. GenoMed`s stock ticker symbol is GMED.

For additional information specific to the new treatment, please visit www.genomedics.com and contact Craig Hall at
941.366.6677 or e-mail at [e-mail] for a GenoMed investor package.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the Company voluntarily
filing a Form 10-SB with the Securities and Exchange Commission and the beneficial nature of the Company`s research
and development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely
result," "are expected to," "will continue," "is anticipated," "potential," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number
of risks and uncertainties. Among other things, competition from existing or new competitors will impact our business; our
research and development is subject to economic, regulatory, governmental, and technological factors. Statements made
herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, we do not undertake, and specifically disclaims any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X83802625

SOURCE GenoMed, Inc.

CONTACT: Media, Russell LaMontagne, [phone], for GenoMed, Inc.;
or Investors, Craig Hall of GenoMed, Inc., [phone]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Hier mal eine Übersicht über die Firma:

About Us
GenoMed is a medical genomics company. GenoMed is working to apply experience in clinical
medicine to medical genomics (the study of how genes function in the cause, progression and
treatment of disease) for the development new treatments, better use of existing therapies and
creation of more accurate gene-based tests for known diseases. By targeting genes
(identifying which genes contribute to specific diseases), we hope to make medicine less
invasive and more proactive.

What We Do
Drug discovery: Once GenoMed identifies a gene target without an existing therapy, the
company pursues strategic alliances with large, research-oriented pharmaceutical companies
to develop new drugs against the target.

Maximizing existing drugs through new clinical indications: In many cases existing
drugs may be viable treatments for targets GenoMed identifies. For example, GenoMed has
demonstrated that a proprietary regimen of ACE inhibitors can dramatically delay the onset of
Type-2 diabetes. New indications do not require the rigorous FDA review process and can be
approved and implemented relatively quickly.

Gene-based diagnostic tests: Millions of people die each year from disease and
thousands more die from negative responses to drugs. GenoMed`s diagnostics identify the
genes that cause disease in order to potentially attack disease before symptoms ever become
visible and to determine which drugs should be prescribed to a person based on his or her
unique genetic makeup.

Competitive Position
Like the science of genomic medicine, GenoMed takes a targeted and efficient approach to
developing new treatments, better using existing therapies and creating gene-based tests for
known diseases. Our clinical experience has helped us to identify a class of single nucleotide
polymorphisms (SNPs) that we believe has strong associations with several common
diseases. Our clinical perspective, combined with proprietary, inexpensive, ultra-high
throughput genotyping, gives us the ability to target disease-causing genes accurately and
quickly. In addition, we dedicate a significantly higher percentage of resources directly to
research compared to the industry average. Our ability to move much more quickly than larger,
more bureaucratic corporations maximizes our intellectual property produced per dollar spent.

History
GenoMed was inspired by Dr. David Moskowitz`s research on the angiotensis I-converting
enzyme (ACE) during the mid 1990s. His lab discovered that ACE was a "master" disease
gene. ACE was found to be associated with about approximately 40 common, serious
diseases such as type 2 diabetes, cancer, and even psychiatric disease. Moskowitz, a
nephrologist, treated 1,000 of his own patients based on his knowledge of the potential of
targeting the ACE. His early efforts produced dramatic results -- the rate of progression of
kidney disease due to high blood pressure was reduced by an average of 400% in both African
American and Caucasian male patients. Through this new treatment, patients that were
expected to reach dialysis in 4 years were delayed by an average of 16 years in reaching
end-stage kidney disease. Patient outcomes for kidney failure due to type 2 diabetes,
atherosclerotic peripheral vascular disease, and emphysema (COPD) were equally exciting. In
February 2001 Moskowitz founded GenoMed with the help of industry veterans Jerry White,
Richard Kranitz and Peter Brooks.

[Bombenleger]

Genomic Medicine

Medical genomics is the study of how genes function in the cause, progression and treatment
of disease. By identifying the genes that cause disease, it is possible to target the most
appropriate drugs for each individual and, possibly, treat diseases before they happen.
Although more than 99% of human DNA sequences are the same across the population,
variations in DNA sequences can have a major impact on the progression and treatment of
disease. Single nucleotide polymorphisms (SNPs) are DNA sequence variations that occur
when a single nucleotide (A, T, C or G) in the genome sequence is altered. It is widely believed
that SNPs predispose people to disease or influence their response to drugs, which make the
study of SNPs of tremendous value for developing pharmaceutical products or medical
diagnostics. SNPs are also evolutionarily stable --not changing much from generation to
generation --making them easy to follow in population studies.

[Bombenleger]

Technology and Approach

GenoMed`s two primary initiatives are the Disease GeneNet™ and HealthChip™. The Disease
GeneNet is the set of single nucleotide polymorphisms (SNPs) GenoMed uses to locate
disease genes. The Disease GeneNet is currently made up of 1,620 SNPs; GenoMed is
working to expand the net to include up to as many as 100,000 SNPs. The probability of
identifying disease genes increases proportionally with the number of SNPs in the Disease
GeneNet. Once the disease genes are identified, disease-associated SNPs are placed onto a
single DNA chip, the HealthChip, for clinical diagnostic testing.

[Bombenleger]

Targeted Diseases

Currently collections are underway or scheduled for the following diseases:

Type 2 diabetes (also called "adult-onset diabetes," or NIDDM)
End-stage kidney disease due to type 2 diabetes
Heart Attack due to Type 2 Diabetes
Stroke due to Type 2 Diabetes
High blood pressure
End-stage kidney disease due to high blood pressure
Heart Attack due to high blood pressure
Stroke due to high blood pressure
Breast cancer
Lung cancer
Prostate cancer
Colon cancer

GenoMed would be delighted to discuss collaborations with qualified groups that are
dedicated to solving specific diseases. Please contact us at [e-mail].

[Bombenleger]

Board of Directors

David W. Moskowitz, MD- Chairman and Chief Medical Officer
Peter C. Brooks, MBA, MA- Board Member
Richard A. Kranitz, J.D. - Corporate Secretary and Board Member
Jerry E. White, MBA- President, Chief Executive Officer and Board Member

David W. Moskowitz, MD- Chairman and Chief Medical Officer
Dr. Moskowitz majored in Chemistry (summa cum laude) at Harvard College, Biochemistry
(first class honours) at Merton College, Oxford, and received an MD (cum laude) from the
Harvard-MIT Division in Health Sciences and Technology (Harvard Medical School). He trained
for 7 years in Internal Medicine and Nephrology at Washington University School of Medicine in
St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine.
From 1994 to 1997, Dr. Moskowitz experienced first hand the clinical effectiveness of knowing
a disease-associated gene (the angiotensin converting enzyme, or ACE, gene). Dr. Moskowitz
is a pioneer in the field of medical genomics, and has been recognized for his groundbreaking
treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic
renal failure due to hypertension or type II diabetes.

Back to top

Peter C. Brooks, MBA, MA- Board Member
Peter has twenty years of investment management, management consulting, private
consulting, business development and corporate management experience in the Asian and
US markets. He is a founding partner of CornerStone Partners, an investment management
firm focused on hedge funds and the international markets. Prior to establishing CornerStone
in 1997, he founded and managed his own private equity investment firm (1981-1997),
Naushon Capital LLC, Boston. Through Naushon Capital Peter participated in the acquisition,
financing or restructuring over 20 companies in a variety of businesses ranging from
companies involved in sophisticated medical research to high technology and innovative
sports equipment manufacturing and home services. Before establishing Naushon Capital, he
was a management consultant with McKinsey & Company in Washington, D.C. and New York.
Peter graduated from Harvard College and earned his MBA and MA from Stanford University.

Back to top

Richard A. Kranitz, J.D. - Corporate Secretary and Board Member
Richard Kranitz has been an attorney in private practice since 1970, with an emphasis in
securities, banking and business law. He is a 1969 graduate of the University of Wisconsin
Law School and served for a year as an assistant to a federal judge. During the past 30 years
he has served as a consultant to, and a director of, over 30 private companies and
professional, civic, and charitable organizations. Since 1990 he has been a director of the
Grafton State Bank, a subsidiary of Merchants & Manufacturers Bancorporation (symbol: MMBI).
Among other publicly registered firms on whose boards he serves are Harp & Eagle, Ltd.
(symbol: HARP) and Mentor Capital Consultants, Inc. (symbol: MCAP). He also served for a
number of years as a director of Mental Health of Ozaukee County, Inc., a non-profit
organization promoting mental health and care for the mentally ill. Mr. Kranitz earned his B.S.
degree from the University of Wisconsin - Milwaukee and his J.D. degree from the University of
Wisconsin - Madison.

Back to top

Jerry E. White, MBA- President, Chief Executive Officer and Board Member
Jerry E. White is a seasoned executive with over 25 years of experience in all facets of
business spanning both the public and private sectors. Mr. White has been in strong demand
as a consultant to more than 200 businesses for his business development, financing,
strategic planning, marketing, production and governmental contracting experience and skills.
Mr. White has also taught business and management courses through the University of
Wisconsin system, where he was the Director of the Department of Business and
Management. Mr. White has served on numerous Boards and committees of both business
and civic organizations in various capacities, from Chairman to Member. Most recently, Mr.
White served as Chairman, CEO and co-founder of Innovative Control Systems, Inc. (ICS)
Accutech, a healthcare security company that designs and manufactures high tech security for
hospitals and nursing facilities. ICS Accutech is the leader in the industry of infant security, and
recently developed a DNA testing and identification system to prevent mother-baby switching.
Jerry E. White is a retired U.S. Army Major where he served in various positions such as
Instructor and Test Pilot, Command and Staff positions, Research and Development, and
combat tours. Jerry has been awarded over 50 military decorations and awards for combat and
distinguished service. He earned his B.S. in Business from the University of Tampa and his
M.B.A. from Troy State University. He also holds a commercial pilot`s license.

[Bombenleger]

Partnerships/Strategic Alliances

American Diabetes Association ("ADA")

BioCollections Worldwide, Inc.

DNAPrint Genomics, Inc

DW Coordinating Center(DWCC)

Muna, Inc.

Orchid BioSciences

[Bombenleger]

The Market

The medical industry is currently a one trillion dollar a year market and is expanding at a rapid
pace. The recent completion of the Human Genome Project has changed the way we view the
treatment of disease and signifies a revolution in the medical industry.

Genomics is in its infancy and is already a multi billion dollar industry worldwide. During the
next decade, cutting-edge genomic companies will be the catalyst for extraordinary medical
advances. The largest pharmaceutical companies in the world such as Bristol-Myers Squibb,
Merck, Pfizer, and Johnson & Johnson, to name only a few, have recognized the value of
genomics, and understand that it will reshape the medical industry as we know it.

[Bombenleger]

GenoMed, Inc. Licenses Treatment Regimen to La Clinica

ST. LOUIS, May 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that
it has signed an agreement to license its ACE inhibitor treatment regimen to La Clinica, a free medical clinic serving the
Hispanic population of St. Louis. Terms of the Licensing Agreement were not disclosed.

La Clinica is a rapidly growing medical clinic that was founded in 1993 to serve the healthcare needs of the Latino
community in the St. Louis area. GenoMed`s treatments will be administered to La Clinica patients under the close
supervision of GenoMed.

Large pharmaceutical companies such as Pfizer and Bristol-Myers Squibb already donate prescription drugs to La Clinica
for use by La Clinica`s patients. The physicians and medical students seeing patients at La Clinica all volunteer their time.

Dr. William Chignoli, founder and Executive Director at La Clinica, stated that, "GenoMed`s drug regimen appears to delay
and, if taken early enough, even prevent complications of diabetes and hypertension. GenoMed`s patient outcomes data
are superior to anything that I have read in the medical literature to date." Dr. Chignoli further commented, "The need for
such a treatment is especially great in this patient population. Almost half of our patients have type 2 diabetes, and it affects
them at a much earlier age than the Caucasian population. There is little money available for surgery or hospitalization for
these patients, so the best approach is to keep them healthy. GenoMed`s treatment is helping to accomplish this."

David W. Moskowitz, GenoMed`s Chairman and Chief Medical Officer will initially oversee the administration of the
treatment regimen at La Clinica.

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide.

A GenoMed press conference will be held at La Clinica Health Center (3646 Fairview Ave., St. Louis, MO; tel.
314-664-5565) on Thursday, May 23, 2002 immediately following Lieutenant Governor Joe Maxwell`s press conference
introducing the Missouri Senior Rx Program, to be held at the same location.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to the Company`s treatment
and the Health Chip(TM) technology and the beneficial nature of the Company`s research and development approach and
business model. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will
continue," "is anticipated," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially
from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Among other
things, competition from existing or new competitors will impact our business; our research and development is subject to
economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press
release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not
undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X82427452

SOURCE GenoMed, Inc.

[Bombenleger]

GenoMed, Inc. Signs Letter of Intent With Healthcare Management Company

ST. LOUIS, May 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that
it has signed a Letter of Intent to license its ACE inhibitor treatment regimen to the physicians under management by the
Saint Louis Management Group, Inc. Saint Louis Management Group is a healthcare management company serving 3,800
physicians located in Missouri, Illinois, Arkansas, and Louisiana, including 1,000 physicians in the St. Louis area.

Saint Louis Management Group, founded in 1985 by Michael Wood, is a leading physician management company
specializing in group purchasing and physician education. GenoMed`s treatments will be administered by Saint Louis
Management Group`s physicians under GenoMed`s close supervision.

Michael Wood, President and CEO of Saint Louis Management Group, stated that "GenoMed`s drug regimen is exactly
what we are looking for to distinguish our physicians in the marketplace. Our physicians are committed to improving patient
outcomes, which GenoMed can clearly deliver. We are confident that patients in the Midwest, especially in the `Show Me`
state, will seek out physicians who can demonstrate superior outcomes. GenoMed`s patient outcomes data are superior to
anything that I or many of my physicians have seen yet in the medical literature." Mr. Wood further commented, "Most
patients want to avoid surgery or hospitalization, so the best approach is to keep them healthy. GenoMed`s treatment
regimen will help us to accomplish this."

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "We are extremely pleased to have Saint
Louis Management Group join GenoMed`s licensing program. We`re excited about the growing number of physician
organizations which are embracing GenoMed`s mission of preventive molecular medicine. Saint Louis Management Group
represents hundreds of thousands of new patients who will be eligible for GenoMed`s treatment regimens. This
collaboration is significant because the potential revenues to be derived from this licensing agreement will be earmarked for
the discovery of new disease genes. Collaborations such as this allow us to continue the development of new treatments
and products such as the Company`s Healthchip(TM). More importantly, we are licensing treatment regimens that have the
potential to dramatically improve patients` quality of life. I`ve seen how important these treatment regimens can be in over
3000 patient-years of clinical experience with my own patients."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica
Health Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) on Thursday, May 23, 2002 to discuss licensing
the same treatment to La Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. The press
conference was held jointly with Lieutenant Governor Joe Maxwell, who encouraged senior citizens to sign up for Missouri
Senior Rx Program, and urged improvement in minority health outcomes.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Health Chip(TM) technology, the beneficial nature of the Company`s relationship with Saint
Louis Management Group, and the Company`s research and development approach and business model. The words or
phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated,"
"potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected
in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether
the Company will have sufficient financing to conduct its research and development; (b) how competition from existing or
new competitors will impact the Company`s business, and (c) the fact that the Company`s research and development is
subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the
Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to
reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56884138

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Signs Letter of Intent With Leading Healthcare Management Company

ST. LOUIS, Jun 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. ("the Company" or "GenoMed")
(National Quotation Bureau`s Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics biotechnology
company, announced today that it has signed another Letter of Intent to license its ACE inhibitor treatment regimen to the
physicians under management by Parks HealthCare, Inc. Parks HealthCare is a healthcare management company serving
1,800 physicians located in Arizona and New Mexico.

Parks HealthCare was founded in 1985 by Sue Parks, R.N., and is a leading physician management company specializing
in group purchasing for physicians located in the Southwestern United States. According to the Letter of Intent, Parks
HealthCare would offer GenoMed`s treatments to its physicians, who would then provide GenoMed`s treatments to their
patients under GenoMed`s close supervision.

Sue Parks, President and CEO of Parks HealthCare, stated that "GenoMed`s program is an extremely exciting offering for
the Phoenix market where we have a broad diversity of demographics including the important category of aging
baby-boomers and snow-birds. Our physicians are committed to improving patient outcomes at all stages of life and are
looking for programs that can support this commitment. GenoMed`s regimen can clearly deliver outcomes. The exciting
part is that patients will seek out our physicians based upon this arrangement. It is a win-win for our physicians and the
general patient population."

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, stated, "We are extremely pleased to have Parks
HealthCare join the growing number of physician organizations participating in GenoMed`s licensing program. The fact that
large physician organizations are joining our licensing program is a validation of our mission, our treatments and our
scientific and business approach. Parks HealthCare`s physicians currently care for hundreds of thousands of patients, many
of whom will be eligible for GenoMed`s treatments. This and our other collaborations will generate licensing revenues for
GenoMed. As with all of our revenue sources, we will dedicate them to the discovery of new disease genes."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl.

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. In May, GenoMed announced an agreement with Saint Louis
Management Group representing more than 3,800 physicians,
http://www.genomedics.com/index.cfm?action=investor&drill=053002." target="_blank" rel="nofollow ugc noopener">http://www.genomedics.com/index.cfm?action=investor&drill=053002.

GenoMed also recently held a press conference at La Clinica Health Center (3646 Fairview Ave., St. Louis, MO; tel.
314-664-5565) to discuss licensing the same treatment to La Clinica for its Hispanic population, who have a 50%
prevalence rate of diabetes. The press conference was held jointly with Lieutenant Governor Joe Maxwell, who
encouraged senior citizens to sign up for Missouri Senior Rx Program, and urged improvement in minority health outcomes.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email:
[e-mail], or visit GenoMed at http://www.genomedics.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company) treatments, and the beneficial nature of the Company`s relationship with Parks HealthCare, Inc. and the
Company`s research and development approach and business model. The words or phrases "would be," "will allow,"
"intends to," "will likely result," "are expected to," "will continue," "is anticipated," "potential," "estimate," "project," or similar
expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a
result of a number of risks and uncertainties, including but not limited to: (a) whether we will have sufficient financing to
conduct our research and development; (b) competition from existing or new competitors will impact our business, and (c)
our research and development is subject to economic, regulatory, governmental, and technological factors. Statements
made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless
otherwise required by applicable law, we do not undertake, and specifically disclaims any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of
such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X53937076

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED,
fax: [phone], [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Neoe]

Sehnlichst erwarte ich die WKN.

[Bombenleger]

GenoMed, Inc. Finds Many More Disease Targets for Its ACE Inhibitor Treatment Regimen

ST. LOUIS, Jun 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC
Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based
medical genomics biotechnology company, announced today that it has answers to
many of the questions suggested by Mary Duenwald in her New York Times article
of June 25, 2002, "Familiar Blood Pressure Drugs Find an Array of Novel Uses"
(http://www.nytimes.com/2002/06/25/health/25ACE.html). The article reported that
ACE inhibitors might be like aspirin, with uses for many more diseases than
originally thought. Why this should be so is still unknown, according to the
article. GenoMed believes that it has many of the missing pieces of this large
and exciting puzzle.

GenoMed thinks it knows which common diseases will benefit from use of ACE
inhibitors, based on genotyping 6,414 Caucasian and African American hospital
patients and 3,959 kidney dialysis patients for the ACE deletion/deletion
genotype. The results are to be published later this year, and predict which
diseases should benefit from ACE inhibition. They include complications of high
blood pressure and diabetes in both Caucasians and African Americans, some of
which were mentioned in the New York Times article, such as stroke, heart
attack, and heart failure, and some which were not, such as kidney failure,
diabetic eye disease (diabetic retinopathy), diabetic nerve disease (diabetic
neuropathy), and peripheral vascular disease.

Additional diseases which GenoMed has found which may benefit from ACE
inhibition include unrelated diseases like glaucoma, degenerative joint disease
("osteoarthritis"), and emphysema. Common psychiatric diseases such as bipolar
affective disorder (manic depression), depression, and schizophrenia may also
benefit.

In addition, basal cell skin cancer, which is the most common cancer among
Caucasians, as well as cancers of the lung, prostate, colon, head and neck, and
bladder, may benefit from ACE inhibition, especially if given preventively. Less
common solid cancers such as cancer of the kidney and pancreas, and lymphoma and
chronic leukemia also appear likely to benefit from preventive treatment with an
ACE inhibitor.

All of these diseases were found to have an ACE D/D frequency higher than among
"control" patients. The strength of this association varied somewhat by
ethnicity and gender, leaving open the possibility that clinical outcomes may
also vary according to ethnicity and gender, as GenoMed has already found in a
small number of diseases.

GenoMed has found that a higher than conventional dose of a particular ACE
inhibitor yielded superior clinical outcomes for male patients with chronic
renal failure due to high blood pressure or type 2 diabetes, as well as a
smaller number of patients with peripheral vascular disease and emphysema.
Paradoxically, African American patients with diabetic kidney disease did better
than Caucasian patients, which runs counter to the prevailing "wisdom" about ACE
inhibitors. These results are to be published in the August/September issue of
"Diabetes Technology and Therapeutics."

GenoMed has applied for patents on these treatment regimens, which will serve as
the starting point for the Company to extend its results to the additional
diseases mentioned above.

The Company has also developed a hypothesis for how ACE may be involved in these
many different diseases. According to David Moskowitz, MD, Chairman of GenoMed,
"The ACE deletion/deletion genotype reveals a kind of `Mississippi River`
connecting many common human diseases. Seemingly unrelated diseases like
cardiovascular disease, psychiatric disease, and cancer are actually related to
one another through sharing excess activity of the ACE enzyme. ACE appears to be
the starting point or `headwaters` of a common disease pathway leading to most
common human (and animal) diseases. This knowledge raises the possibility that
many common diseases could be delayed or perhaps prevented altogether with the
right dose of the right ACE inhibitor taken for the right length of time. Since
all of these diseases are associated with aging, this treatment may combat aging
itself."

GenoMed has applied for patents on the above material, and is actively enrolling
physicians and patients in the U.S. and abroad to use its Clinical Outcomes
Improvement Machine(TM), based on its discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient
outcomes by identifying the genes that cause disease. A recent St. Louis
Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1…
reported that the company has applied for patents based on its finding that the
ACE gene is associated with nearly 40 common, age-related diseases. The Company
has filed patent applications on its new treatments for both human and
veterinary use. A video version of the company`s treatment results for chronic
kidney failure is available at
http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed
is currently working to license its treatments to physicians and healthcare
systems worldwide. GenoMed recently held a press conference at La Clinica Health
Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) in, May 2002 to
discuss licensing the same treatment to La Clinica for its Hispanic population,
who have a 50% prevalence rate of diabetes. GenoMed also recently announced that
it is holding discussions with large physician organizations located in the
Midwestern and Southwestern United States as part of its strategy to work
directly with physicians to deliver its unique treatments to patients. The
Company is also discussing a collaboration with an outcomes management company
to capture patient outcomes accurately.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX
314-977-0042, email: [e-mail] visit GenoMed at
www.genomedics.com.

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s
(the Company) treatments, its research and development approach and business
model. The words or phrases "would be," "will allow," "may," "intends to," "will
likely result," "are expected to," "will continue," "is anticipated,"
"potential", "estimate," "project," or similar expressions are intended to
identify "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could differ materially
from those projected in the forward-looking statements as a result of a number
of risks and uncertainties, including but not limited to: (a) whether we will
have sufficient financing to conduct our research and development; (b) whether
competition from existing or new competitors will impact our business, and (c)
our research and development being subject to economic, regulatory,
governmental, and technological factors. Statements made herein are as of the
date of this press release and should not be relied upon as of any subsequent
date. Unless otherwise required by applicable law, we do not undertake, and
specifically disclaim any obligation, to update any forward-looking statements
to reflect occurrences, developments, unanticipated events or circumstances
after the date of such statement.



MAKE YOUR OPINION COUNT - Click Here

http://tbutton.prnewswire.com/prn/11690X18000986

SOURCE GenoMed, Inc.



CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or fax,

[phone], or [e-mail]



URL: http://www.genomedics.com

http://www.prnewswire.com


Copyright (C) 2002 PR Newswire. All rights reserved.

[2 PAC]

22.01.02 0,06$
03.07.02 0,026$

u got it?

2 PAC

[Bombenleger]

GenoMed, Inc. Announces Publication of Its New Treatment Next Month

ST. LOUIS, Jul 16, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that
results of its novel ACE inhibitor treatment have been accepted for publication.

The article, entitled "From Pharmacogenomics to Improved Patient Outcomes," details the outcomes of 200 African American
and Caucasian men with chronic kidney disease due to high blood pressure, diabetes, or polycystic kidney disease, as well as
800 male patients with high blood pressure alone. The study was an observational one; patients were followed over a three
year period without being randomized to a "placebo" control.

Highlights of the paper include the following: 1) no adverse events were seen, in large part because the new treatment
carefully controlled serum potassium, which is often elevated in patients with kidney failure; 2) African American patients did
as well or better than Caucasian patients; 3) if begun early enough, the new treatment could reverse kidney disease in patients
with high blood pressure or diabetes.

As seen in other studies, autosomal dominant polycystic kidney disease showed no improvement when treated with higher
doses of an ACE inhibitor.

The United States is currently experiencing an epidemic of kidney failure, with a 5% increase annually in the number of
patients on kidney dialysis. Minorities are hit especially hard. There are now 200,000 patients on kidney dialysis, at a cost of
$18 billion annually. In 2010, it is estimated that there will be 300,000 patients on dialysis, at a much higher cost. Nearly 90%
of patients on kidney dialysis lost their kidney function because of diabetes or high blood pressure. About 5% have polycystic
kidney disease.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, commented, "Publication of our patient outcomes in
a peer-reviewed journal is a key step in the validation and dissemination of our novel treatment method. The sooner we can
convince patients and physicians about the usefulness of our method, the sooner we believe we can stop the current epidemic
in kidney disease."

The article will be published in late August in Diabetes Technology and Therapeutics, a bimonthly journal.

GenoMed has applied for patents on the above material, and expects soon to be enrolling physicians and patients in the U.S.
and abroad in its Clinical Outcomes Improvement Progam(TM), based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a number of common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica Health
Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) in, May 2002 to discuss licensing the same treatment to La
Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. GenoMed also recently announced that it is
holding discussions with large physician organizations located in the Midwestern and Southwestern United States as part of its
strategy to work directly with physicians to deliver its unique treatments to patients.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, fax, [phone], email:
[e-mail] visit GenoMed at www.genomedics.com.

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the publication of the article
"Pharmacogenomics and Improved Patient Outcomes." The words or phrases "would be," "will allow," "may," "intends to,"
"believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential", "estimate," "project," or similar
expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result
of a number of risks and uncertainties, including but not limited to: (a) whether we will have sufficient financing to conduct our
research and development; (b) whether competition from existing or new competitors will impact our business, and (c) our
research and development being subject to economic, regulatory, governmental, and technological factors. Statements made
herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X81482238

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer, GenoMed, Inc., +-1-877-GENOMED, or
fax, [phone], email: [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Completes Agreement To Manage National Distribution Of Its Clinical Outcomes
Improvement Program(TM)

ST. LOUIS, Jul 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc (OTC Pink Sheets: GMED), ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has
completed a contract with Saint Louis Management Group, Inc. ("SLMG") to manage the national distribution of its Clinical
Outcomes Improvement Program(TM) to physician organizations.

Saint Louis Management Group is a leading physician management company specializing in group purchasing and physician
education.

Michael Wood, President and CEO of Saint Louis Management Group, stated that, "We are excited to be chosen to lead the
effort to distribute GenoMed`s program to other physician management groups across the U.S. With the continuing downward
pressure on physician income, every physician organization is seeking relationships that can both improve the quality of health
care for the consumer and allow physicians to enhance their revenue. The GenoMed program does both. It`s the right
program at the right time for both the patient and the physician. It`s a great program."

Under the agreement, SLMG will oversee the distribution of GenoMed`s Clinical Outcomes Improvement Program(TM) to
groups that provide management services to physician organizations across the country. GenoMed is currently negotiating
agreements with several large physician organizations in several markets. GenoMed recently announced the signing of a letter
of intent with a large Physician Management Organization in Arizona. SLMG will coordinate with these organizations to
ensure maximum participation by their physicians and patients in GenoMed`s program. SLMG will also introduce GenoMed`s
program to its own 3,800 physicians in the Midwest and southern United States.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are delighted to have Saint Louis Management agree to lead our
physician organization partnering efforts. Through SLMG we hope to attain a wide distribution of our Clinical Outcomes
Improvement Program(TM). We`re excited about physician organizations that are embracing GenoMed`s mission of
preventive molecular medicine, and becoming part of our Clinical Outcomes Improvement Network(TM). Our Clinical
Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients` health dramatically while
positively differentiating a physician`s practice in the medical marketplace. It`s a real win-win situation for patients and their
physicians."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Clinical Outcomes Improvement Program(TM), the beneficial nature of the Company`s
relationship with Saint Louis Management Group, and the Company`s research and development approach and business
model. The words or phrases "would be," "will allow," "intends to," "will likely result," "promises," "are expected to," "will
enable," "will continue," "is anticipated," "potential," "estimate," "project," or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) whether the Company will have sufficient financing to conduct its research and development;
(b) how competition from existing or new competitors will impact the Company`s business; (c) the success of physician
management groups with which we may have agreements or otherwise affiliate ourselves with; and (d) economic, regulatory,
governmental, and technological factors which may affect the Company`s business. Statements made herein are as of the
date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable
law, the Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to
reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X20836789

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., [phone], or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Signs Letter Of Intent With Drug Discovery Company

ST. LOUIS, Jul 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has
signed a Letter of Intent to potentially partner with AngioDesign, Inc. ("AngioDesign") in drug discovery projects.
AngioDesign is a privately held company that designs and develops new drugs directed to proven disease targets using
structure-guided design tools ("smart molecule design").

AngioDesign was founded by Mario Ehlers, Ed Sturrock, and Ravi Acharya, who recently were the first to determine the 3-D
crystal structure of ACE (angiotensin I-converting enzyme), one of the most important cardiovascular disease targets. The
development of domain-selective ACE inhibitors that are expected to supercede first-generation inhibitors is an important
R&D focus for the company. Further, AngioDesign will develop its drug discovery efforts in designing new compounds
directed at proven disease targets, especially those associated with the vasculature and the circulation.

Two additional co-founders of AngioDesign are Dr. Fred Wagner and Dr. Bart Holmquist, who have extensive biotechnology
experience, most recently at Restoragen, Inc.

Dr. Mario Ehlers, President of AngioDesign, stated that, "We are very pleased to be considered as a partner of GenoMed`s
for drug discovery. Our way of thinking about disease causation is very much in line with GenoMed`s. We believe GenoMed`s
approach to finding disease-predisposition genes will give us a large number of targets to work on."

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "We are extremely pleased to have identified
AngioDesign as a potential partner in our drug discovery process. Once GenoMed finds a disease- predisposition gene, a
number of steps are required before that knowledge can be translated into better patient care. First, the protein product of the
disease-causing gene must be imaged in three dimensions, which often requires X-ray crystallography. Next, existing drugs
must be screened for their ability to bind to the protein; much of which can be accomplished by computer. If no existing drug
exists, then new drugs must be designed to fit the binding site in the protein. Again, this can be done by computer, using
so-called "rational drug design" or "smart-molecule design." The principals of AngioDesign have already proven their ability to
successfully navigate many of these subsequent steps successfully, and we look forward to working together in the future."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with nearly 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently announced that it is holding discussions with
large physician organizations located in the Midwestern and Southwestern United States as part of its strategy to work
directly with physicians to deliver its unique treatments to patients.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail]
or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the beneficial nature of any future
partnering arrangements by the Company with AngioDesign, Inc. to conduct drug discovery projects. The words or phrases
"would be," "will allow," "may," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "potential",
"estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the
forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether we will
have sufficient financing to conduct our research and development; (b) whether competition from existing or new competitors
will impact our business, and (c) our research and development being subject to economic, regulatory, governmental, and
technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any
subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to
update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the
date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X10312877

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., [phone], or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com

[Bombenleger]

GenoMed, Inc. Completes Agreement To Manage Southwestern US Distribution Of Its Clinical
Outcomes Improvement Program(TM)

ST. LOUIS, Aug 08, 2002 /PRNewsire-FirstCall via Comtex/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company"
or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has completed
a contract with Parks Health Care, Inc of Phoenix, Arizona ("PHC") to introduce its Clinical Outcomes Improvement
Program(TM) to physician organizations in Arizona, New Mexico and Nevada.

Parks Health Care is a leading consultant to physicians specializing in group purchasing and physician education.

Sue Parks, President and CEO of Parks Health Care, stated that, "It is appropriate that Phoenix has been designated as one
of the centers for GenoMed`s medical genomics effort. The Phoenix area is a mecca for healthy baby-boomers and retirees.
There is huge interest among our Physicians in becoming GenoMed-certified. It allows our physicians to bring the benefits of
the Genomic Revolution to their patients and help supplement their income as well. The GenoMed program delivers a great
value."

Under the agreement, PHC will introduce and support the program of GenoMed`s Clinical Outcomes Improvement
Program(TM) to more than 2,500 physicians across the Southwestern United States.

GenoMed is currently negotiating agreements with large physician organizations in markets across the United States.
GenoMed is also in conversations with international markets as well.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are delighted to have Parks Health Care actively involved in our
program. They are a great partner in a great market. The Phoenix/Sun Valley population of retirees and baby- boomers are a
perfect fit for our Clinical Outcomes Improvement Program(TM). We anticipate that our novel program will allow a better
quality of life and greatly reduce overall health care costs that are the usual burden of aging."

Dr. Moskowitz added, "We continue to be excited about the growing number of physician organizations that are embracing
GenoMed`s mission of preventive molecular medicine, and who are interested in becoming part of our Clinical Outcomes
Improvement Network(TM). We hope in the coming years to capture a significant portion of practicing physicians in the
United States."

The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients` health
dramatically while positively differentiating a physician`s practice in the medical marketplace.

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Clinical Outcomes Improvement Program(TM), the beneficial nature of the Company`s
relationship with Parks Health Care, and the Company`s research and development approach and business model. The words
or phrases "would be," "will allow," "intends to," "will likely result," "promises," "anticipate," "are expected to," "will enable,"
"will continue," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those
projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a)
whether the Company will have sufficient financing to conduct its research and development; (b) how competition from
existing or new competitors will impact the Company`s business; (c) the success of physician management groups with which
we may have agreements or otherwise affiliate ourselves; and (d) economic, regulatory, governmental, and technological
factors which may affect the Company`s business. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake,
and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56555672

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., 1-877-436-6633, or fax,
[phone], email: [e-mail]

URL: http://www.prnewswire.com
http://www.genomedics.com

[Bombenleger]

GenoMed, Inc. Announces Drug Therapy to Avoid Dialysis in Acute Kidney Failure

ST. LOUIS, Aug 13, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed), a St. Louis, Missouri-based medical genomics biotechnology company, announced today a new
drug treatment based on pilot data that avoids dialysis in the setting of acute kidney failure.

Based on pilot data conducted by Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, the drug regimen
avoided the need for dialysis in over 80% of adults in the hospital with acute kidney failure. This drug regimen has also been
used with similar success for neonates with acute kidney failure in the Neonatal Intensive Care Unit. The same treatment
should be useful in avoiding non-function of transplanted kidneys after harvesting from donors and immediately after
placement into recipients.

Dr. Moskowitz gave the patients a loading dose and an infusion of an already existing medication, aminophylline. This specific
treatment has not been used before, and is based on the physiology of why the kidney shuts down in acute kidney failure. On
August 8, 2001, Genomed filed its first application for world-wide patent protection involving aminophylline in acute kidney
failure.

"Despite the introduction of kidney dialysis within the past 50 years," says Dr. Moskowitz, "acute kidney failure is still
associated with a 50% mortality rate. It is a devastatingly expensive problem for all concerned. Avoiding dialysis may be the
first step towards reducing the costs and mortality of acute kidney failure. This treatment should also be especially useful in
settings without ready access to kidney dialysis machines, such as third-world hospitals or disaster sites such as earthquakes."

Dr. Moskowitz, a nephrologist trained at Harvard, Oxford and Washington University in St. Louis, was formerly a staff
physician at the St. Louis VA Medical Center and assistant professor at Saint Louis University School of Medicine. "The
mission of GenoMed is to serve as a Next Generation Disease Management(TM) company, translating insights about how
disease is caused into better treatments for patients," Dr. Moskowitz said. "We have compelling data that is immediately
valuable to patients, their physicians, and health care payers, and which offers immediate cost savings."

About GenoMed

GenoMed is a biotech company based in St. Louis, Missouri, that is working to translate knowledge of disease pathways into
better patient outcomes as rapidly and safely as possible. Building on its initial discoveries and success, GenoMed is dedicated
to (1) identifying additional disease-associated genes and pathways; (2) working on new treatments using existing drugs
whenever possible; and, (3) developing new drugs when necessary to stop disease-causing pathways. GenoMed`s stock ticker
symbol is GMED.

For additional information, please visit www.genomedics.com and/or contact Krissy Fischer at 1-877-GENOMED or e-mail at
[e-mail] for additional written information pertaining to GenoMed.

This press release contains forward-looking statements, including those statements pertaining to the beneficial nature of the
drug therapy that avoids kidney dialysis in acute kidney failure. The words or phrases "would be," "will allow," "intends to,"
"will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to
identify "forward-looking statements." Actual results could differ materially from those projected in the forward-looking
statements as a result of a number of risks and uncertainties. Among other things, competition from existing or new
competitors will impact our business; our research and development is subject to economic, regulatory, governmental, and
technological factors; and our experience with aminophylline may not be replicated by other physicians. Statements made
herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, the Company does not undertake, and specifically disclaims any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of
such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X40643941

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Announces Drug Therapy Which May Avoid Prolonged Mechanical Ventilation in
Neonates

ST. LOUIS, Aug 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today a new
drug treatment that has the potential to avoid prolong mechanical ventilation in newborns born prematurely with inadequate
lung development.

Based on research conducted by Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, the drug regimen
could avoid the need for prolonged mechanical ventilation in newborns whose lungs failed to develop adequately. The
treatment involves a growth factor that is present throughout pregnancy in the amniotic fluid, and which causes normal lung
development. Dr. Moskowitz`s research established the precise values of the growth factor, epidermal growth factor, at
different times in pregnancy. Right before a child is born, the level of the growth factor doubles, probably accounting for the
burst in lung development that normally happens before birth. In babies born prematurely, this last burst of lung development
fails to occur, and they must be kept on mechanical ventilation for weeks at a time, at great expense.

This specific treatment has not been used before in humans, although animal studies have already shown promise. The
treatment will require well- designed clinical trials and FDA approval before it can be used widely. The advantage of Dr.
Moskowitz`s data is that the levels of epidermal growth factor normally present can be used in clinical trials. In this way, just
enough growth factor can be used to achieve the desired effect (proper lung development), but higher doses can be avoided,
with their risk for unwanted side effects. On August 13, 2001, Genomed filed its first application for world-wide patent
protection involving epidermal growth factor to hasten lung development during pregnancy or in the newborn period, and
ramipril to treat pulmonary hypertension in the newborn.

"There are several conditions responsible for inadequate lung development in babies," says Dr. Moskowitz. "Epidermal growth
factor, at the right dose, should be able to reverse most of these problems. What`s surprising is that the fetal kidneys release
epidermal growth factor into the urine, which is all that amniotic fluid is -- fetal urine -- even before the 16th week of
pregnancy. This explains why children whose kidneys don`t develop normally also don`t have normal lung development (called
Potter`s syndrome). Their mothers have too little amniotic fluid. But it`s not just the fluid, it`s the growth factor in the fluid,
that`s important to replace. Knowing what levels of epidermal growth factor need to be in amniotic fluid throughout pregnancy
should help physicians achieve normal lung development. In babies who are suddenly born prematurely, we will know what
level of epidermal growth factor to instill in their ventilator fluid. This treatment should improve on the current treatment,
which is to instill surfactant in the ventilator fluid, since epidermal growth factor causes lung cells to make surfactant. We look
forward eagerly to collaborating with obstetricians and neonatalogists to prove that these treatments will work."

Dr. Moskowitz, a nephrologist trained at Harvard, Oxford and Washington University in St. Louis, was formerly a staff
physician at the St. Louis VA Medical Center and assistant professor at Saint Louis University School of Medicine. "The
mission of GenoMed is to serve as a Next Generation Disease Management(TM) company, translating insights about how
disease is caused into better treatments for patients," Dr. Moskowitz said. "We already have compelling data that is valuable
to patients, their physicians, and health care payers, and which offers potentially enormous cost savings."

About GenoMed

GenoMed is a biotech company based in St. Louis, Missouri, that is working to translate knowledge of disease pathways into
better patient outcomes as rapidly and safely as possible. Building on its initial discoveries and success, GenoMed is dedicated
to (1) identifying additional disease-associated genes and pathways; (2) working on new treatments using existing drugs
whenever possible; and, (3) developing new drugs when necessary to stop disease-causing pathways. GenoMed`s stock ticker
symbol is GMED.

For additional information, please visit www.genomedics.com and/or contact Krissy Fischer at 1-877-GENOMED or e-mail at
[e-mail] for additional written information pertaining to GenoMed.

This press release contains forward-looking statements, including those statements pertaining to the beneficial nature of the
drug therapy that aids in lung development in babies. The words or phrases "would be," "will allow," "intends to," "will likely
result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify
"forward-looking statements." Actual results could differ materially from those projected in the forward-looking statements as
a result of a number of risks and uncertainties. Among other things, competition from existing or new competitors will impact
our business; our research and development is subject to economic, regulatory, governmental, and technological factors; and
our expectations about epidermal growth factor may not be borne out by actual clinical experience, or the treatment may
cause unacceptable side effects. Statements made herein are as of the date of this press release and should not be relied upon
as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and the Company specifically
disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events
or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X28139371

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or e-mail,
[e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Signs Letter of Intent for Distribution of Its Clinical Outcomes Improvement
Program(TM) to Brazil

ST. LOUIS, Mo., Aug 27, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has
signed a Letter of Intent with Dr. Mario Abbud-Filho to introduce its Clinical Outcomes Improvement Program(TM) to
physicians in Brazil.

Dr. Abbud-Filho is a leading academic nephrologist and expert in kidney transplantion practicing in Sao Paolo, the most
populous state in Brazil. Dr. Abbud-Filho is currently a tenured professor at the Medical School of Rio Preto, where he went
to medical school, and where he recently served as Vice- Director. After finishing his nephrology training in Brazil, he spent
two years in Paris and two additional years at Harvard Medical School as a post- graduate researcher in transplantation
immunology. He is a former Executive Director of the Brazilian Transplant Organ Association, and currently serves as
Editor-in-Chief of two medical journals, the Brazilian Transplantation Journal and the Medical Journal of the Medical School
of Rio Preto.

Dr. Abbud-Filho stated that, "It is appropriate that Brazil has been designated as one of the countries for GenoMed`s medical
genomics effort. Brazil is the economic and population giant of South America and is larger than the United States. Our
President has made affordable, state-of-the-art health care a national priority. Brazilian physicians have long been interested
in embracing the best available medicine. Collaboration with GenoMed will allow our physicians to bring the benefits of the
Genomic Revolution to their patients and will help supplement their income as well. The GenoMed program delivers enormous
value for all concerned."

Under the proposed agreement, Dr. Abbud-Filho will help introduce and support GenoMed`s Clinical Outcomes Improvement
Program(TM) to physicians in Sao Paolo and elsewhere in Brazil.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are delighted to have a physician as accomplished and as well
respected nationally and internationally as Dr. Abbud-Filho involved in our program of preventive molecular medicine. Brazil is
obviously a huge market. Dr. Abbud-Filho`s superb training and demonstrated ability to remain at the cutting edge of medicine,
his skill at educating his peers, and the respect he has already earned professionally among his peers and his patients, makes
him an ideal partner for GenoMed."

Dr. Moskowitz added, "We are thrilled by the growing number of physicians who are embracing GenoMed`s mission of
preventive molecular medicine, and who are interested in becoming part of our Clinical Outcomes Improvement Network
(TM). We hope in the coming years to capture a significant portion of practicing physicians not only in the United States, but
abroad as well. "

The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients` health
dramatically while positively differentiating a physician`s practice in the medical marketplace.

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Clinical Outcomes Improvement Program(TM), the beneficial nature of the Company`s
relationship with Dr. Abbud-Filho, and the Company`s research and development approach and business model. The words or
phrases "would be," "will allow," "intends to," "will likely result," "promises," "anticipate," "are expected to," "will enable," "will
continue," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those
projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a)
whether the Company will have sufficient financing to conduct its research and development; (b) how competition from
existing or new competitors will impact the Company`s business; (c) the success of physicians with whom we may have
agreements or otherwise affiliate ourselves; and (d) economic, regulatory, governmental, and technological factors which may
affect the Company`s business. Statements made herein are as of the date of this press release and should not be relied upon
as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and specifically
disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events
or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X48606440

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Internationally Known Oncology Surgeon Frank E. Johnson Joins GenoMed`s Scientific Advisory
Board

Ridgeland, MS, SEP 03, 2002 (EventX/Knobias.com via COMTEX) -- ST. LOUIS--(September 3, 2002) -GenoMed, Inc.
(OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology
company, announced today that Dr. Frank E. Johnson has joined its Scientific Advisory Board.

Dr. Johnson is a leading academic surgeon with special expertise in cancer surgery. He is currently Professor of Surgery at
St. Louis University School of Medicine, and Chief of Surgery at the St. Louis VA Medical Center.

Dr. Johnson received both his undergraduate degree (with Phi Beta Kappa honors) and his M.D. degree from the University
of Minnesota. He then trained in general and oncologic surgery at UCLA, the University of Washington in Seattle, and the
University of Colorado in Denver. He spent four years as a Surgical Research Fellow, first at the University of California,
San Francisco, and then at the Memorial Sloan-Kettering Cancer Center in New York. His surgical training was interrupted
for two years in 1969-71. He spent those two years on active duty as

a Navy surgeon, in part with the First Marine Division in DaNang, Vietnam, for which he received the Bronze Star and the
Navy Commendation Medal.

Dr. Johnson is the author of over 200 journal articles and a dozen books and book chapters. He has been featured in 14 videos
demonstrating advanced surgical techniques, and he received an award for excellence in student teaching for three years in a
row at St. Louis University School of Medicine. He is on the editorial boards of 6 surgical journals, and a member of 31
professional

societies, including serving as co-founder of the Children`s Heart Fund in Minneapolis, a non-profit organization now known as
Children`s Heart Link. As a Visiting Professor supported by the Royal College of Surgeons in 1986-87 and by the Central
Surgical Association Foundation in 1995, he has taught at more than a dozen of the finest surgical hospitals in England, Wales,
Italy, and the Netherlands. In 1982, he was a Visiting Professor in Brazil. His scientific interests range from the molecular
aspects of cancer to the cost of cancer surgery.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are honored to have Dr. Johnson agree to join our Scientific Advisory
Board. He is a surgeon with impeccable training, outstanding skills as an educator, and an enormous breadth of scientific
interests. He is extremely well-respected nationally and internationally."

Dr. Moskowitz added, "Perhaps the most unique thing about Dr. Johnson is that, despite his extraordinary skill at general
surgery and cancer surgery in particular, he is committed to early detection of disease using the most advanced technology
possible. He would much rather prevent disease than operate on it. He is an expert on the cost of health care, and is
committed to improving patient outcomes while reducing healthcare costs. Dr. Johnson brings to GenoMed`s Scientific
Advisory Board the ability to see the clinical `Big Picture.`"

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article

(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1…

reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common,
age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use. A
video version of the company`s treatment results for chronic kidney failure is available at

http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, the beneficial nature of the Company`s relationship with Dr. Johnson, and the Company`s research
and development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely result,"
"promises," "anticipate," "are expected to," "will enable," "will continue," "potential", "estimate," "project," or similar expressions
are intended to identify "forward-looking statements." Actual results could differ materially from those projected in the
forward-looking statements as a result of a number

of risks and uncertainties, including but not limited to: (a) whether the Company will have sufficient financing to conduct its
research and development; (b) how competition from existing or new competitors will impact the Company`s business; (c) the
success of physicians with whom we may have agreements or otherwise affiliate ourselves; and (d) economic, regulatory,
governmental, and technological factors which may affect the Company`s business. Statements made herein are as of the
date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable
law, the Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to
reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by 10 minutes. To get all
Knobias alerts in real-time daily, visit http://www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a financial information provider serving retail investors and trading professionals. Knobias
collects and maintains real-time and historical market intelligence on all U.S. securities, with special emphasis on
Over-the-Counter (OTC) stocks. Knobias provides customers with two core products: 1. Knobias FUNDAMENTALS: A
comprehensive web-based database of fundamental research covering thousands of U.S. securities; 2. Knobias RAiDAR: A
web-based desktop application that delivers thousands of real-time, intraday alerts daily. RAiDAR alerts include real-time
news, filings, trading alerts, earnings alerts, coverage alerts and critical corp actions.

KNOBIAS DISCLAIMER: Knobias has received no compensation from the Company or Companies mentioned in this story.
Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities
mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be
liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is
expressly prohibited without prior written consent of Knobias.com, LLC.

CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx


Copyright 2002 Knobias.com, LLC, All rights reserved.

[Bombenleger]

GenoMed, Inc. Signs Letter of Intent with Physician Services Company

ST. LOUIS, Sep 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED), ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it has
signed a letter of intent with Health Services Initiatives, Inc. ("HSI") to introduce its Clinical Outcomes Improvement
Program(TM) to physicians in Chicago and parts of the United Kingdom.

Health Services Initiatives is a leading consultant to physicians specializing in developing strategies to protect and raise
physician income.

John R. Dolan, FCA (the British equivalent of "CPA"), who is the President and CEO of HSI, stated, "From our discussions,
physicians are hugely interested in the promise of the genomic revolution to improve quality and outcomes for their patients.
At the same time, they are looking to offset the lowered reimbursement levels and higher expenses caused by managed care.
The value proposition of the GenoMed program could not be more timely both in the United States and abroad."

Under the agreement, HSI will introduce and support GenoMed`s Clinical Outcomes Improvement Program(TM) to more
than 3,000 physicians in Chicago and other target markets across the United States and in parts of the United Kingdom.

GenoMed is currently negotiating agreements with large physician organizations in markets across the United States.
GenoMed is also in conversations with international markets as well.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are delighted to have HSI and particularly John Dolan actively
involved in our program. Mr. Dolan`s breadth of experience, excellent reputation, and credibility with physicians could not be
better. Health Services Initiatives is well known in health care circles in Chicago and has long-standing ties to some of the
largest hospital and provider systems in the country. In addition, Mr. Dolan`s background and relationships in the United
Kingdom are a real plus as we push the program to international levels."

Dr. Moskowitz continued, "Through Health Services Initiatives we hope to attain a wide distribution of our Clinical Outcomes
Improvement Program(TM). We continue to be excited about the growing number of physician organizations that are
embracing GenoMed`s mission of preventive molecular medicine, and becoming part of our Clinical Outcomes Improvement
Network(TM). We hope in the coming years to capture a significant portion of practicing physicians in the United States and
internationally as well."

The Clinical Outcomes Improvement Program(TM) is designed to enable physicians to improve their patients` health
dramatically while positively differentiating a physician`s practice in the medical marketplace.

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Clinical Outcomes Improvement Program(TM), the beneficial nature of the Company`s
relationship with Health Services Initiatives, Inc., and the Company`s research and development approach and business model.
The words or phrases "would be," "will allow," "intends to," "will likely result," "promises," "are expected to," "will enable," "will
continue," "is anticipated," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially
from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not
limited to: (a) whether the Company will have sufficient financing to conduct its research and development; (b) how
competition from existing or new competitors will impact the Company`s business; (c) the success of physician management
groups with which we may have agreements or otherwise affiliate ourselves; and (d) economic, regulatory, governmental, and
technological factors which may affect the Company`s business. Statements made herein are as of the date of this press
release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company
does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X71606788

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer, GenoMed, Inc., +1-1-877-GENOMED, or fax,
[phone], or email: [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Announces Publication of Its Treatment to Delay Chronic Kidney Failure

ST. LOUIS, Sep 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Bulletin Board GMED) ("the
Company" or "GenoMed") a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its
novel treatment method for chronic kidney disease was published in the journal Diabetes Technology and Therapeutics.

Diabetes Technology and Therapeutics is a peer-reviewed, bimonthly journal which focuses on state-of-the-art treatments for
diabetes. The article, entitled "From Pharmacogenomics to Improved Patient Outcomes: Angiotensin I- Converting Enzyme as
an Example," by Dr. David W. Moskowitz, GenoMed`s Chairman and Chief Medical Officer, appeared in the
August/September issue, released today. Angiotensin I-converting enzyme`s common abbreviation is ACE. The study
describes the use of two currently available ACE inhibitors, quinapril and ramipril, in the successful treatment of four diseases:
chronic kidney disease due to type 2 diabetes, chronic kidney disease due to high blood pressure, poor circulation due to high
blood pressure, and emphysema. For the latter two diseases, only case reports were available.

Dr. David Moskowitz, GenoMed`s Chairman, said, "I am delighted that Dr. David Klonoff, the Editor of Diabetes Technology
and Therapeutics, and the journal`s reviewers, have considered my observational clinical experience worthy of publication. I
found that a higher dose of a specific ACE inhibitor, quinapril, was extremely effective in delaying chronic kidney disease due
to diabetes or high blood pressure in both white and black men. In fact, if the treatment was started early enough in the course
of the disease, kidney failure was reversed altogether, the first time this has ever been reported."

Dr. Moskowitz added, "This has immediate implications for the 60 million Americans with high blood pressure and the 20
million Americans with diabetes, as well as the primary care physicians who care for them. If the pilot data for emphysema
can be replicated, then an additional 16 million Americans with emphysema could benefit from GenoMed`s patented treatment
methods. GenoMed is launching the Next Generation of Disease Management(TM) to commercialize these results."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Next Generation Disease Management(TM) program, and the Company`s research and
development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely result,"
"promises," "anticipate," "are expected to," "will enable," "will continue," "potential", "estimate," "project," or similar expressions
are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of
1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of
risks and uncertainties, including but not limited to: (a) whether the Company will have sufficient financing to conduct its
research and development; (b) how competition from existing or new competitors will impact the Company`s business; (c) the
success of physicians with whom we may have agreements or otherwise affiliate ourselves; and (d) economic, regulatory,
governmental, and technological factors which may affect the Company`s business. Statements made herein are as of the
date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable
law, the Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to
reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X75592234

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed Chief Medical Officer to Present Data at Two Conferences in September

ST. LOUIS, Sep 11, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Bulletin Board: GMED)- ("the
Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its
Chairman and Chief Medical Officer, David Moskowitz MD, will be presenting the company`s data at two conferences next
week.

On Wednesday, September 18, Dr. Moskowitz will present a poster on the first day of the World Genomics Symposium &
Exposition being held in Atlantic City (http://www.world-genomics.com). His poster will be entitled "Improved Patient
Outcomes Thanks to Medical Genomics: Diabetic and Hypertensive Renal Failure in White and Black Men." The poster will
describe kidney patients` outcomes using GenoMed`s patent-pending treatment, which was published yesterday.

On Friday of next week (September 20), Dr. Moskowitz will address the 7th Annual Disease Management Congress meeting
at the Sheraton Hotel & Towers, Chicago, IL (http://www.nmhcc.org/dmc). His topic will be "Next Generation Disease
Management(TM): From Pharmacogenomics to Improved Patient Outcomes." His talk will describe a new pro-active form of
Disease Management, guided by knowledge of disease genes, which only GenoMed currently offers.

Dr. Moskowitz stated, "GenoMed has treatment programs which could potentially benefit hundreds of millions of patients
world-wide. It is incumbent on the company to get the word out. Presentation of our data at genomic and clinical conferences
is one of the most effective ways to inform colleagues and decision-makers of what we have to offer. I am excited to do my
part."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 40 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use. A video version of the company`s treatment
results for chronic kidney failure is available at http://216.234.225.2/external.asp?b=571&id=49&from=pl

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail],
or visit GenoMed at http://www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Next Generation Disease Management(TM) program, the effect of presenting at these two
professional conferences, and the Company`s research and development approach and business model. The words or phrases
"would be," "will allow," "intends to," "will likely result," "promises," "anticipate," "are expected to," "will enable," "will continue,"
"potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in
the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether the
Company will have sufficient financing to conduct its research and development; (b) how competition from existing or new
competitors will impact the Company`s business; (c) the success of physicians with whom we may have agreements or
otherwise affiliate ourselves; and (d) economic, regulatory, governmental, and technological factors which may affect the
Company`s business. Statements made herein are as of the date of this press release and should not be relied upon as of any
subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and specifically disclaims
any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X36822671

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, +1-877-GENOMED, fax, 314-977-0042,
or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Announces Publication of Study Suggesting Many Disease Indications for Its New
Treatment

ST. LOUIS, Sep 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED), ("the
Company" or "GenoMed") a St. Louis, Missouri-based medical genomics biotechnology company, announced today that a
research article documenting the many diseases which may benefit from its novel ACE inhibitor treatment will be published
soon.

The article, entitled "Is Angiotensin I-Converting Enzyme a `Master` Disease Gene?" is a study in the new field of genomic
epidemiology. It describes the results of genotyping 10,400 hospital and clinic patients for the ACE gene polymorphism,
including nearly 4,000 patients on kidney dialysis. In all, results are presented for 219 disease categories in white men, 78
diseases in white women, 196 disease categories in black men, 132 diseases in black women, and about a dozen diseases
in Hispanic patients.

The conclusion of the paper is that effective tissue ACE inhibition may possibly improve patient outcomes in an
extraordinary number of diseases: perhaps as many as 60-70% of diseases in whites, and 40% in blacks. At least 30% of
the small number of diseases tested in Hispanic dialysis patients ought to benefit from effective tissue ACE inhibition.

These diseases include almost all categories of cardiovascular disease; almost all common cancers except prostate and
breast-in where the data are still confusing; and several major psychiatric diseases. Even the rate of infection with the HIV
virus, and progression to AIDS, look as if they might be decreased with effective tissue ACE inhibition.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, commented, "We are extrapolating from
epidemiologic odds ratios to prediction of clinical benefit. This is always risky, but our own extraordinary patient outcomes
published earlier this month appear to justify this leap of faith. It will take several years, at the least, to show which of these
many diseases we can actually slow down. In the case of cancer, which probably takes decades to develop, it may take
decades, too, to show a beneficial effect of our treatment. Given the safety record of our treatment so far, and the
seriousness of the diseases we`re talking about, to me it seems that the potential benefit of trying our new treatment
outweighs the risk of trying something new."

Dr. Moskowitz continued, "I am the first to admit that this whole story sounds incredible, since we`re all used to thinking in
terms of just one disease at a time. But our extreme good fortune is brought to us by the ACE gene. It happens to be an
incredibly old and important gene for life on earth, and our data suggest that it is at the origin of most common diseases in
humans, and, probably, vertebrates, that is, animals with a backbone. I personally believe we have hit one of the largest
clinical jackpots of all time."

Dr. Moskowitz ended by saying, "The sooner we can convince patients and physicians about the potential usefulness of our
method, the sooner we believe we can cut healthcare costs and slow current worldwide epidemics in cardiovascular
disease, cancer, and perhaps, if our data hold up, even HIV."

The article will be published in the October/November issue of Diabetes Technology and Therapeutics.

GenoMed has applied for patents on the above material, including the many disease indications for its new treatment and
the new treatment itself. GenoMed is actively enrolling physicians and patients in the U.S. and abroad in its Clinical
Outcomes Improvement Progam(TM), based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a number of common, age-related diseases. These diseases are
the subject of the article described here. The Company has filed patent applications on its new treatments for both human
and veterinary use. A video version of the company`s treatment results for chronic kidney failure is available at
http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica
Health Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) in, May 2002 to discuss licensing the same
treatment to La Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. GenoMed also recently
announced that it is holding discussions with large physician organizations located in the Midwestern and Southwestern
United States as part of its strategy to work directly with physicians to deliver its unique treatments to patients.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email:
[e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the publication of the article "Is
Angiotensin I-Converting Enzyme a `Master` Disease Gene?" The words or phrases "would be," "ought to," "will allow,"
"may," "intends to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential", "estimate,"
"project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking
statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our molecular
epidemiologic results can be replicated; (b) whether our molecular epidemiologic results will actually lead to clinical
improvements; (c) whether we will have sufficient financing to conduct our research and development; (d) whether
competition from existing or new competitors will impact our business, and (e) our research and development being subject
to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press
release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not
undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X42216813

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer, GenoMed, Inc., +1-1-877-GENOMED, or fax,
[phone], or email: [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Company News and Press Releases From Other Sources:

GenoMed, Inc. Announces Discovery of Molecular Mechanism for Most Chronic Diseases of
Adulthood

ST. LOUIS, Oct 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that a research article
describing the molecular mechanism causing most chronic diseases of adulthood will be published soon.

The article is entitled "Is Angiotensin I-Converting Enzyme a Mechanosensor?" It draws from molecular evolution, biochemistry,
fluid mechanics, and systems analysis to propose a simple yet elegant mechanism that unifies most of human pathology. The
article claims that angiotensin I- converting enzyme (ACE) could be associated statistically with so many different diseases
only because the enzyme plays a critical function in the circulation, and the circulation controls all the tissues in the body.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "The form of the enzyme which is present in our
circulation is the result of a duplication of the ancestral gene, which occurred about 500 million years ago. This was the
Cambrian Period, when vertebrates (animals with a backbone) first arose. In fact, there was an explosion in the number of
species, called the Cambrian `explosion.` Animals changed from an open to a closed circulation, and the pressure in the
circulation went up from a few millimeters of mercury (mm Hg) to 100-200 mm Hg. The paper claims that none of this would
have been possible without the duplicated form of the ACE gene. But humans and all other animals with a backbone pay a price
-- we age, because the duplicated form of the gene is activated by turbulent flow with each heart beat."

Dr. Moskowitz added, "This is the missing piece of the puzzle that everyone has been looking for. I feel the same way Watson
and Crick did when they realized that the phosphate groups of DNA were on the outside of the molecule, not the inside as
everyone else thought. Because of the treatment we`ve also worked out, the beauty of this discovery is that it can benefit
everybody immediately."

The article will be published in the November/December issue of Diabetes Technology and Therapeutics.

GenoMed has applied for patents on the above material, including the many disease indications for its new treatment and the
new treatment itself. GenoMed is actively enrolling physicians and patients in the U.S. and abroad in its Clinical Outcomes
Improvement Progam(TM), based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases. How ACE starts
these diseases is the subject of the article described here. The Company has filed patent applications on its new treatments for
both human and veterinary use. A video version of the company`s treatment results for chronic kidney failure is available at
http://216.234.225.2/external.asp?b=571&id=49&from=pl

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica Health
Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) in May 2002, to discuss licensing the same treatment to La
Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. GenoMed also recently announced that it is
holding discussions with large physician organizations located in the Midwestern and Southwestern United States as part of its
strategy to work directly with physicians to deliver its unique treatments to patients.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED, FAX [phone], email: [e-mail] or
visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the publication of the article "Is
Angiotensin I-Converting Enzyme a Mechanosensor?" The words or phrases "would be," "ought to," "will allow," "may," "intends
to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential", "estimate," "project," or similar
expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number
of risks and uncertainties, including but not limited to: (a) whether our molecular model is supported by subsequent research;
(b) whether our molecular epidemiologic results will actually lead to clinical improvements; (c) whether we will have sufficient
financing to conduct our research and development; (d) whether competition from existing or new competitors will impact our
business, and (e) our research and development being subject to economic, regulatory, governmental, and technological factors.
Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date.
Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such
statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X62560023

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, +1-877-GENOMED, or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Company News and Press Releases From Other Sources:

GenoMed, Inc. Announces Publication of Study Suggesting ACE is Behind Most Diseases

ST. LOUIS, Oct 23, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. -- ("the Company" or "GenoMed") (OTC Pink
Sheets Symbol: GMED), a St. Louis, Missouri- based medical genomics biotechnology company, announced publication today
of a research article which identifies a large number of common diseases that may benefit from treatment with an ACE inhibitor.
ACE is an abbreviation for "angiotensin I converting enzyme." Drugs which inhibit this enzyme are called "ACE inhibitors," and
have been in clinical use since 1976. Several ACE inhibitors are available as generic drugs now.

The research article, entitled "Is Angiotensin I-Converting Enzyme a `Master` Disease Gene?" is a study in the new field of
genomic epidemiology. It describes the results of genotyping 10,400 hospital and clinic patients for the ACE gene
polymorphism, including nearly 4,000 patients on kidney dialysis. In all, results are presented for 219 disease categories in
white men, 78 diseases in white women, 196 diseases in black men, 132 diseases in black women, and about a dozen
diseases in Hispanic patients.

The conclusion of the paper is that effective ACE inhibition may possibly improve patient outcomes in an extraordinary number
of diseases: perhaps as many as 70% of all common diseases in whites, and at least 40% of common diseases in blacks.

These diseases include almost every kind of heart disease including most complications of diabetes and high blood pressure;
almost all common cancers except prostate and breast cancer; and several major psychiatric diseases. Even the rate of
infection with the HIV virus, as well as progression to AIDS, might be decreased with effective ACE inhibition.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, commented, "This paper suggests that most common
adult diseases are related in that they all start with activation of the ACE enzyme. This is quite a new idea, and one with
immediate clinical consequences. Last month in the same journal, we showed the benefit of completely inhibiting ACE for four
diseases including diabetic and hypertensive kidney disease. It will take several years at least to show which additional
diseases we can slow down. In the case of cancer, which probably takes decades to develop, it may take decades, too, to
show a beneficial effect of our treatment."

Dr. Moskowitz continued, "Given the overall safety record of ACE inhibitors and of our treatment in particular, and the
seriousness of the diseases we`re talking about, I believe that the potential benefits of GenoMed`s approach far outweigh the risk
of trying nothing new."

The article is published in the September/October issue of Diabetes Technology and Therapeutics, volume 4, number 5, pages
683-711.

GenoMed has applied for patents on the above material, including the many disease indications for its new treatment and the
new ACE-inhibitor-based treatment itself. GenoMed is actively enrolling physicians and patients in the U.S. and abroad in its
Clinical Outcomes Improvement Progam(TM), based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a number of common, age-related diseases. These diseases are the
subject of the article described here. The Company has filed patent applications on its new treatments for both human and
veterinary use.

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to patients and physicians worldwide. For example, GenoMed recently licensed its treatment to La Clinica Health
Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]), whose Hispanic population has a nearly 50% prevalence rate of
diabetes.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877- 436-6633), FAX [phone], email:
[e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the implications of the article "Is
Angiotensin I-Converting Enzyme a `Master` Disease Gene?" The words or phrases "would be," "ought to," "will allow," "may,"
"intends to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential", "estimate," "project," or
similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a
number of risks and uncertainties, including but not limited to: (a) whether our molecular epidemiologic results can be
replicated; (b) whether our molecular epidemiologic results will actually lead to clinical improvements; (c) whether we will have
sufficient financing to conduct our research and development; (d) whether competition from existing or new competitors will
impact our business, and (e) our research and development being subject to economic, regulatory, governmental, and
technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any
subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to
update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the
date of such statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X37448608

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

Company News and Press Releases From Other Sources:

GenoMed Chief Medical Officer to Present Data at Diabetes Meeting

Ridgeland, MS, OCT 24, 2002 (EventX/Knobias.com via COMTEX) -- ST. LOUIS, Oct 24, 2002 -- GenoMed, Inc. (OTC Pink
Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company,
announced today that its Chairman and Chief Medical Officer, David Moskowitz, M.D., will be presenting the company`s data at
a conference next week.

Next Friday, November 1st, Dr. Moskowitz will present a poster at the Second Annual Diabetes Technology Meeting being held
in Atlanta (www.diabetestechnology.org). His poster will be entitled "Improved Patient Outcomes Thanks to Medical Genomics:
Diabetic Nephropathy in White and Black Men." The poster will describe kidney patients` outcomes using GenoMed`s

patent-pending treatment, which was published in the journal Diabetes Technology & Therapeutics on September 10th. Kidney
failure could be slowed considerably if the treatment is begun early enough. Kidney failure could even be reversed if GenoMed`s
treatment was begun before a patient`s serum creatinine, a common measure of kidney function, climbed past 2 milligrams per
deciliter.

The poster will also present what other complications of type 1 and type 2 diabetes, in addition to kidney failure, might benefit
from GenoMed`s treatment. These include heart disease, stroke, poor circulation of the legs which often leads to amputations,
eye damage that often leads to blindness ("retinopathy"), and numbness ("neuropathy"). The evidence for these additional
disease targets was published yesterday in the same journal, Diabetes Technology & Therapeutics. No clinical results are yet
available for these additional diseases associated

with diabetes.

Dr. Moskowitz commented, "True to everyone`s expectations, medical genomics is presenting us with a cornucopia of clinical
solutions. What may be surprising to most people is that the clinical pay-off is already here, not a decade or two in the future."

Dr. Moskowitz continued, "It will take years of ongoing clinical research, of course, to find out exactly how rich a jackpot
GenoMed has already hit. We know our ACE inhibitor treatment can prevent diabetic kidney disease, if started early enough.
We need more experience with patients to know if the same treatment will also delay or even prevent other complications of
diabetes. Given how awful diabetes still is, and given how safe and effective our ACE inhibitor

treatment already is, I see little reason why a patient with diabetes wouldn`t consider joining our Clinical Outcomes Improvement
Program(TM) to try to prevent most complications of diabetes."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article

(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1…

reported that the company has applied for patents based on its finding that the ACE gene is associated with over 40 common,
age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its Next Generation Disease Management(TM) program, the effect of presenting at this professional
conference, and the Company`s research and development approach and business model. The words or phrases "would be,"
"will allow," "intends to," "will likely result," "promises," "anticipate," "are expected to," "will enable," "will continue," "potential,"
"estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking
statements

as a result of a number of risks and uncertainties, including but not limited to: (a) the reproducibility of our results in the hands
of other physicians and scientists; (b) whether the Company will have sufficient financing to conduct its research and
development; (c) how competition from existing or new competitors will impact the Company`s business; (d) the success of
physicians to whom we license our treatments; and (e) economic, regulatory, governmental, and technological factors which
may affect the Company`s business. Statements made

herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, the Company does not undertake, and specifically disclaims any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such
statement.

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by 10 minutes. To get all Knobias
alerts in real-time daily, visit http://www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a financial information provider serving retail investors and trading professionals. Knobias collects
and maintains real-time and historical market intelligence on all U.S. securities, with special emphasis on Over-the-Counter
(OTC) stocks. Knobias provides customers with two core products: 1. Knobias FUNDAMENTALS: A comprehensive web-based
database of fundamental research covering thousands of U.S. securities; 2. Knobias RAiDAR: A web-based desktop application
that delivers thousands of real-time, intraday alerts daily. RAiDAR alerts include real-time news, filings, trading alerts, earnings
alerts, coverage alerts and critical corp actions.

KNOBIAS DISCLAIMER: Knobias has received no compensation from the Company or Companies mentioned in this story.
Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities
mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be
liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is
expressly prohibited without prior written consent of Knobias.com, LLC.

CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx


Copyright 2002 Knobias.com, LLC, All rights reserved.

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:

GenoMed Initiates Colon Cancer Gene Discovery Effort

ST. LOUIS, Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that it is going after
colon cancer.

GenoMed will begin work immediately to identify genes associated with colon cancer using its patent-pending process of
disease gene discovery. Based on the Company`s existing SNP research coupled with its knowledge of disease pathways, the
Company hopes to identify at least one gene associated with colon cancer within the first four months of the project.

The Company was contacted in May, 2002 by a 46 year-old white man in previously excellent health who had just been
diagnosed with metastatic colon cancer the month before. His doctor gave him 3 months to live. The patient had learned of
GenoMed`s research and was eager to try anything that might extend his life. Based only on statistical data linking the
angiotensin I-converting enzyme ("ACE") gene to colon cancer, which was published last week,* Dr. Moskowitz worked with the
patient`s physician to determine an appropriate treatment regimen. Since that time, the patient has gained 40 pounds and has
increased his exercise program from a 2-mile daily walk to an 8-mile jog. The patient`s weight and stamina increased while he
was receiving chemotherapy treatments, which is unusual.

Dr. David W. Moskowitz, GenoMed`s Chairman and Chief Medical Officer, commented, "We have identified a statistical link
between colon cancer and the ACE gene. So far, this patient`s response has been encouraging, but it`s still way too early to
know how much our ACE inhibitor treatment has helped. The clinical success we`ve had so far in treating a growing number of
serious diseases strongly suggests to me that we are on the right track. It looks like activation of ACE may be an early event in
a large number of serious diseases. We are racking up much better clinical outcomes against largely unstoppable diseases,
such as diabetic kidney disease, peripheral vascular disease, psoriasis, and emphysema. I sincerely hope colon cancer will be
the next disease to fall, for this patient`s sake."

Dr. Moskowitz continued, "Today we began construction of our Disease GeneNet(TM), concentrating on candidate genes for
colon cancer. We expect to have a completed version of the Disease GeneNet(TM), useful for all human diseases, within the
next 12 to 18 months. We expect to start netting genes associated with colon cancer within the next 4 months, using our first
version of the Disease GeneNet(TM). As we enlarge the Disease GeneNet(TM) for colon cancer with additional candidate SNPs,
we expect to identify and file patents for additional colon cancer genes."

Dr. Moskowitz concluded, "I know, as a physician who watched my own two parents die of colon cancer, exactly how
unrealistic it is to expect to beat colon cancer. But my experience so far with medical genomics gives me faith that it has
extraordinary power. There is simply nothing better than knowing what causes the disease in the first place. Even without any
new drugs, finding colon cancer genes will give us an early warning system for identifying future colon cancer patients. Ideally,
we`ll know exactly who needs early colonoscopy so that their tumors can be removed at an early stage, unlike the patient whom
I`m currently trying to help in an admittedly last- ditch effort."

*Moskowitz, DW. Is Angiotensin I-Converting Enzyme a `Master` Disease Gene? Diabetes Technology & Therapeutics 2002; vol.
4, number 5, pp. 683-711.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases, including colon
cancer. The patient discussed above is using the Company`s patent-pending treatment for colon cancer on an experimental
basis. It is too early to tell if he has received any definitive medical benefit from it, although he is evidently tolerating the
treatment well.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com .

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research expectations, and the Company`s research and development approach and business
model. The words or phrases "would be," "will allow," "intends to," "will likely result," "promises," "anticipate," "are expected
to," "will enable," "will continue," "potential", "estimate," "project," or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) our ability to get adequate samples from patients with colon cancer; (b) the ability of our
collaborators to perform chip-based SNP genotyping; (c) whether the Company will have sufficient financing to conduct its
research and development; (d) how competition from existing or new competitors will impact the Company`s business; (e) the
success of physicians to whom we license our treatments; and (f) economic, regulatory, governmental, and technological
factors which may affect the Company`s business. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake,
and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X36857168

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., [phone], or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:

GenoMed Hires Chief Scientific Officer from Johns Hopkins

ST. LOUIS, Oct 31, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that Paula Hempen,
Ph.D. has joined the Company as its Chief Scientific Officer.

Dr. Hempen has extensive research experience in cancer genetics, the regulation of gene transcription, immunology, and
genomics. Dr. Hempen spent the last three years in the laboratory of Dr. Scott Kern at the Sydney Kimmel Comprehensive
Cancer Center at Johns Hopkins University in Baltimore, Maryland. Dr. Hempen`s research at Hopkins led to the discovery of
two new tumor suppressor genes in pancreatic cancer. Her findings have recently been submitted for publication.

Dr. David Moskowitz, GenoMed`s Chairman, said, "With her cutting-edge experience in molecular biology, bioinformatics,
molecular genetics, immunology and especially cancer genetics, Dr. Hempen is a wonderful addition to the GenoMed team."
Dr. Hempen said, "I am very excited to be a part of the GenoMed team and to begin the adventure of discovery here in my
hometown of St. Louis."

Dr. Moskowitz concluded, "I am thrilled that a scientist of Dr. Hempen`s excellence has joined us, and I am delighted to entrust
our scientific endeavor to her capable hands."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. Two recent publications detail the Company`s unique treatment approach, and the large number of age-related
diseases that it may be applicable to. Having developed a novel treatment for cardiovascular disease, the Company is now
working on an early-warning system for cancer, starting with colon cancer.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, the beneficial effect of Dr. Hempen`s association for the Company, and the Company`s research and
development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely result,"
"promises," "anticipate," "are expected to," "will enable," "will continue," "potential", "estimate," "project," or similar
expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in
the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether the
Company will have sufficient financing to conduct its research and development; (b) how competition from existing or new
competitors will impact the Company`s business; and (c) economic, regulatory, governmental, and technological factors which
may affect the Company`s business. Statements made herein are as of the date of this press release and should not be relied
upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and
specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X05163112

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., [phone], or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

SEC Accepts GenoMed`s Registration Statement

ST. LOUIS, Nov 8, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that the Securities and
Exchange Commission has verbally provided notification to the Company that the Company`s Form 10-SB Registration
Statement has been declared effective as of November 7, 2002.

The Company now plans to make the necessary application to request that its common stock be quoted on the Over The
Counter Bulletin Board (OTC Bulletin Board).

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has
filed patent applications on its new treatments for both human and veterinary use.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) future application to trade on the OTC Bulletin Board. The words or phrases "would be," "will allow," "intends to,"
"will likely result," "promises," "anticipate," "are expected to," "will enable," "will continue," "potential," "estimate," "project," or
similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a
number of risks and uncertainties, including but not limited to: (a) whether the Company will have sufficient financing to conduct
its research and development; (b) how competition from existing or new competitors will impact the Company`s business; and
(c) economic, regulatory, governmental, and technological factors which may affect the Company`s business. Statements made
herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise
required by applicable law, the Company does not undertake, and specifically disclaims any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such
statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X84178774

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[morchel]

....man könnte daraus schließen das es GMED an die BBX schaffen will!

Man kennt die genauen bestimmungen zwar nicht, aber es gibt sicherlich schon vermutungen!

Mindestaktionäranzahl usw....

morchel

[Morgagelchel]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[JavierOxtoa]

der Weg nach unten ist offen, der Weg nach oben unerreichbar!

nichts passt besser auf JEDE von morchels aktien

[Bombenleger]

GenoMed Chairman to Present at Health Promotion Conference in Washington, D.C. in
February

ST. LOUIS, Nov 15, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that its Chairman, David
Moskowitz, M.D., will discuss the role of medical genomics at the Art and Science of Health Promotion Conference to be held
in Washington, D.C. in February, 2003.

The Conference, whose focus this year will be "Transforming the Vision into Reality," will be held at the Omni Shoreham Hotel.
The title of Dr. Moskowitz`s 75-minute Breakout Session is "Health Promotion and Medical Genomics: Mortal Enemies or Best
Friends?" Details of the conference are available at its website, www.HealthPromotionConference.org .

Dr. Moskowitz commented, "The reality of medical genomics is that it can already take the bite out of more and more common
diseases. Even before new drugs hit the market, an early warning system, based on knowledge of a person`s particular disease
genes, will make current medicine extraordinarily powerful. Genomics will be the best tool ever in Health Promotion`s arsenal."

Dr. Moskowitz continued, "In my opinion, whether Health Promotion has any future is the bigger question. The tremendous irony
is that GenoMed has already published a patent-pending treatment that I think could cut 50% of healthcare costs over the next
decade, beginning immediately. The treatment is based on our discovery that angiotensin I-converting enzyme (ACE) appears to
be a master disease gene, not only for humans, but for all vertebrate species. I personally believe we have discovered the
Fountain of Youth. This is exactly the sort of grand-slam home run that people have always dreamed of from biomedical
research. The treatment is available now. It is safe. But apart from my own patients (and my dog), nobody else on the planet is
enjoying the treatment. Plus, we have so far been unable to get significant investment or press coverage, as our most recent
Form 10Q and our press releases make abundantly clear."

Dr. Moskowitz added, "GenoMed is in no way alone. The investment climate has been atrocious for over a year, worse than the
Depression, and one-third of all biotech companies are predicted to go bankrupt in the next 12 months."

Dr. Moskowitz summarized, "I find the situation quite extraordinary. I`m beginning to get the feeling that nobody in the health
care system, other than patients, really wants patient outcomes to improve. Innovation requires risk. So does investment, for
that matter. The financial, political, and bureaucratic incentives in the healthcare system all work strongly against patients, in
the guise of minimizing risk. This is little consolation to patients, whose risk of dying remains 100%, last I checked. I plan to
discuss these obstacles to innovation at the Health Promotion Conference, since the conference specifically focuses on vision
versus reality. What GenoMed has been facing is reality, and reality is always quite instructive. There`s clearly no point in
finding all the disease genes in the world if patients are kept from using this knowledge. Our business model must address
these obstacles squarely and courageously. If we aren`t courageous, how can we expect anyone else to be? Promoting health
by preventing disease above all requires the courage to upset a $2 trillion a year apple-cart."

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article (
http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has
filed patent applications on its new treatments for both human and veterinary use.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) research and development program, the effect of presenting at the Health Promotions Conference, and the
Company`s business model. The words or phrases "would be," "will allow," "intends to," "will likely result," "promises,"
"anticipate," "are expected to," "will enable," "will continue," "potential," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and
uncertainties, including but not limited to: (a) whether the Company will have sufficient financing to conduct its research and
development; (b) how competition from existing or new competitors will impact the Company`s business; and (c) economic,
regulatory, governmental, and technological factors which may affect the Company`s business. Statements made herein are as
of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by
applicable law, the Company does not undertake, and specifically disclaims any obligation, to update any forward-looking
statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X22264605

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:

World Expert on Angiotensin I-Converting Enzyme Joins GenoMed`s Scientific Advisory
Board

ST. LOUIS, Dec 12, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics company, announced today that Sergei Danilov, M.D., Ph.D.,
Dr.Sci. has joined its Scientific Advisory Board.

Dr. Danilov is one of the half-dozen or so world experts on the angiotensin I-converting enzyme (ACE). Between 1986 and 1993,
while Deputy Director of the Cell Biology Department of the National Cardiology Research Center in Moscow, Russia, he
developed over a dozen monoclonal antibodies against ACE. He used these antibodies to probe the role of ACE in normal
physiology and disease. Dr. Danilov is the author of over 80 journal articles, of which 56 relate to ACE.

Dr. David Moskowitz, GenoMed`s Chairman, said, "We are honored to have Dr. Danilov agree to join our Scientific Advisory
Board. He is a biochemist and cell biologist who has contributed as much as anyone to understanding the role that ACE plays
in the body, as well as the diagnostic and therapeutic potential of monoclonal antibodies to this clinically relevant enzyme. Now
that we are signing up patients for our novel treatment approach, we need to have a way to follow them clinically. Dr. Danilov has
agreed to help us develop a diagnostic test to follow how completely we are blocking tissue ACE in individual patients."

Dr. Danilov is the author of six Russian patents and one American patent. He is a world expert in measuring the activity of the
ACE enzyme in blood and tissues. He has agreed to work with GenoMed on the development of a tissue ACE assay for use in
following patients clinically, for which GenoMed has patents pending.

Dr. Danilov said, "It is a delight to have spent my entire professional life working on ACE and to finally have it mean a lot to
patients. I am very excited to be working with GenoMed on this project."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with over 100 common, age-related diseases. The Company has filed
patent applications on its new treatments for both human and veterinary use.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, the beneficial nature of the Company`s relationship with Dr. Danilov, and the Company`s research and
development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely result,"
"promises," "anticipate," "are expected to," "will enable," "will continue," "potential," "estimate," "project," or similar
expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in
the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether the
Company will have sufficient financing to conduct its research and development; (b) how competition from existing or new
competitors will impact the Company`s business; (c) the success of physicians with whom we may have agreements or
otherwise affiliate ourselves; and (d) economic, regulatory, governmental, and technological factors which may affect the
Company`s business. Statements made herein are as of the date of this press release and should not be relied upon as of any
subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and specifically disclaims any
obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X18163468

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:

GenoMed Announces ALLHAT Study is Fatally Flawed

ST. LOUIS, Dec 18, 2002 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc -- ("the Company" or "GenoMed") (National
Quotation Bureau`s Pink Sheets Symbol GMED), a St. Louis, Missouri-based medical genomics company, announced today
that the ALLHAT study published in today`s Journal of the American Medical Association has a fatal research flaw.

ALLHAT, an 8 year study funded by the National Institutes of Health at a cost of over $100 million and involving over 40,000
patients, concluded that lowering blood pressure with a thiazide diuretic was just as effective as therapy with lisinopril, an ACE
inhibitor. An editorial in the same issue of JAMA by Dr. Lawrence J. Appel admitted that this result was surprising.

GenoMed has evidence that lisinopril failed to work better than a thiazide diuretic for two important reasons: it was the wrong
ACE inhibitor to use, and it was used at too low a dose.

Lisinopril is the most polar (hydrophilic, or water-loving) ACE inhibitor on the market. But hydrophilic ACE inhibitors act on only
one of the two active sites of the ACE enzyme, so they inhibit only 50% of the enzyme activity. The ALLHAT investigators
should have used one of the most hydrophobic, or water-hating ACE inhibitors, like quinapril or ramipril, which can inhibit over
97% of ACE enzyme activity. Plus, they should have used a dose high enough to inhibit tissue ACE. This dose is some 30
times higher than the dose required to inhibit serum ACE.

The dose and hydrophobicity of ACE inhibitor make a critical difference in patient outcomes, as demonstrated in an article
recently published by GenoMed`s Chief Medical Officer, Dr. David Moskowitz ("From pharmacogenomics to improved patient
outcomes: angiotensin I-converting enzyme as an example." Diabetes Technology & Therapeutics, vol. 4, no. 4, pp. 519-532,
2002). In the article, the difference between the standard dose of quinapril (40 mg/day, which was the highest dose of lisinopril
used in ALLHAT), and a several-fold higher dose was clear. The lower dose resulted in rapid progression of kidney failure; the
higher dose dramatically reduced the rate of progression of kidney failure, even reversing it when patients were begun early in
the course of their disease, before their serum creatinine had reached 2 milligrams per deciliter.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "I actually was a Principal Investigator for ALLHAT
for two years, from May, 1994 until I resigned in November, 1996. I resigned after a particularly bad month in which several of my
100 ALLHAT patients had a stroke or a heart attack. But none of my other 1,000 patients on high dose quinapril or ramipril had
had any problems for the previous two and a half years. I resigned after reading George Annas` editorial in JAMA on the
occasion of the 50th anniversary of the Nuremberg trials, in which he asked why German doctors hadn`t just said no."

Dr. Moskowitz continued, "For two and a half years I tried to tell the leaders of ALLHAT that they were missing the boat, using
an inadequate dose of the wrong ACE inhibitor. There was abundant research, including from my own lab, proving that
overactivity of ACE caused complications of high blood pressure and diabetes, making effective ACE inhibition the most logical
first treatment for both diseases. In fact, I worked closely with one of the most senior leaders of ALLHAT on a weekly basis. But
my data and my pleading were ignored. Finally, I just couldn`t keep delivering such knowingly inferior care to my ALLHAT
patients. I couldn`t change ALLHAT, but I could just say, `No`."

Dr. Moskowitz summarized, "I am happy to put my patient outcomes up against ALLHAT`s any day of the week. For anyone to
conclude from the ALLHAT study that ACE inhibitors are no better than thiazide diuretics is to persist in the fallacy of the
ALLHAT investigators that all ACE inhibitors are alike, and that low doses are acceptable. Such an attitude defied common
sense, as well as genomic epidemiology, then, and it does so even more today."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases. The Company has
filed patent applications on its new treatments for both human and veterinary use.

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide. GenoMed recently held a press conference at La Clinica Health
Center (3646 Fairview Ave., St. Louis, MO; tel. [phone]) in, May 2002 to discuss licensing its ACE inhibitor treatment to
La Clinica for its Hispanic population, who have a 50% prevalence rate of diabetes. GenoMed also recently announced that it is
holding discussions with large physician organizations located in the Midwestern and Southwestern United States as part of its
strategy to work directly with physicians to deliver its unique treatments to patients.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model. The words or phrases "would be," "ought
to," "will allow," "may," "intends to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential",
"estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking
statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our molecular model is
supported by subsequent research; (b) whether all of our molecular epidemiologic results will actually lead to clinical
improvements; (c) whether we will have sufficient financing to conduct our research and development; (d) whether competition
from existing or new competitors will impact our business, and (e) our research and development being subject to economic,
regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and
specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X82831755

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, +1-877-GENOMED (1-877-436-6633),
fax, [phone], [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.

[morchel]

GMED ist auf den richtigen Weg wie es scheint!

morchel

[Bombenleger]

GenoMed, Inc. Announces Publication of Molecular Mechanism for Most Chronic Diseases
of Adulthood

ST. LOUIS, Jan 2, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based medical genomics biotechnology company, announced today that a research article
describing the molecular mechanism causing most chronic diseases of adulthood has been published.

The article is entitled "Is Angiotensin I-Converting Enzyme a Mechanosensor?" It proposes a simple yet elegant mechanism
that unifies most of human pathology. The article claims that overactivity of angiotensin I- converting enzyme (ACE) can be
associated statistically with so many different diseases only because the enzyme plays a critical function in the circulation, and
the circulation controls all the tissues in the body.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "The form of the enzyme which is present in our
circulation is the result of a duplication of the ancestral gene, which occurred about 500 million years ago. This was the
Cambrian Period, when vertebrates (animals with a backbone) first arose. In fact, there was an explosion in the number of
species, called the Cambrian `explosion.` Animals changed from an open to a closed circulation, and the pressure in the
circulation went up from a few millimeters of mercury (mm Hg) to 100-200 mm Hg. The paper claims that none of this would
have been possible without the duplicated form of the ACE gene. But humans and all other animals with a backbone pay a price
-- we age, because the duplicated form of the gene is activated by turbulent flow with each heart beat."

Dr. Moskowitz added, "This is the missing piece of the puzzle that everyone has been looking for. Because of the treatment
we`ve also worked out, the beauty of this discovery is that it can benefit people immediately."

The article was published in the November/December issue of Diabetes Technology and Therapeutics.

GenoMed has applied for patents on the above material, including the many disease indications for its new treatment and the
new treatment itself. GenoMed is actively enrolling physicians and patients in the U.S. and abroad in its Clinical Outcomes
Improvement Progam(TM), based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease. A recent St. Louis Business Journal article
(http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) reported that the company has applied for patents
based on its finding that the ACE gene is associated with a large number of common, age-related diseases. How ACE starts
these diseases is the subject of the article described here. The Company has filed patent applications on its new treatments for
both human and veterinary use.

Consistent with the Company`s goal to improve patient outcomes globally, GenoMed is currently working to license its
treatments to physicians and healthcare systems worldwide.

For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX [phone], email:
[e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the validity of the hypothesis
presented in the article "Is Angiotensin I-Converting Enzyme a Mechanosensor?" The words or phrases "would be," "ought to,"
"will allow," "may," "intends to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential,"
"estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking
statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our molecular model is
supported by subsequent research; (b) whether our molecular epidemiologic results will actually lead to clinical improvements;
(c) whether we will have sufficient financing to conduct our research and development; (d) whether competition from existing or
new competitors will impact our business, and (e) our research and development being subject to economic, regulatory,
governmental, and technological factors. Statements made herein are as of the date of this press release and should not be
relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically
disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X09860345

SOURCE GenoMed, Inc.

CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed, Inc. Seeks Volunteers for New Emphysema Treatment

ST. LOUIS, Jan 14, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking volunteers with emphysema
to test its new treatment approach.

GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases,
including emphysema. ACE stands for "angiotensin converting enzyme."

Using genomic epidemiology, GenoMed has discovered that patients with emphysema tend to have overactivity of their ACE
enzyme. A logical approach is to inhibit ACE, using ACE inhibitors. GenoMed has already been able to prolong a patient`s life
with terminal emphysema by seven years, suggesting that ACE inhibition may be the first treatment since oxygen to delay the
disease.

The research supporting this new treatment was published in the fall, 2002 in Diabetes Technology and Therapeutics.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that
cause disease.

To volunteer, please contact GenoMed`s Chief Medical Officer, Dr. David Moskowitz, tel. [phone], fax [phone], email:
[e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the
Company`s) treatments, its research and development approach and business model, and the suggestion that emphysema may
respond to effective inhibition of ACE. The words or phrases "would be," "ought to," "will allow," "may," "estimate," "project," or
similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a
number of risks and uncertainties, including but not limited to: (a) whether our treatment approach results in improved outcomes
for patients with emphysema; (b) whether we will have sufficient funding and collaboration to conduct our research and
development; and (c) our research and development`s being subject to economic, regulatory, governmental, and technological
factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent
date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any
forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such
statement.

SOURCE GenoMed, Inc.

CONTACT: Dr. David Moskowitz, Chief Medical Officer of GenoMed, Inc.,
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed seeks Collaborators in Trial to Speed Lung Maturity in Newborns

ST. LOUIS, Jan 28, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking collaborators in Neonatal
Intensive Care Units (NICU`s) to test a new treatment for lung immaturity in the newborn. Lung immaturity is common in babies
born more than a month prematurely.

The treatment involves a growth factor that is present throughout pregnancy in the amniotic fluid, and which causes normal lung
development. Dr. Moskowitz, GenoMed`s Chairman, has established the precise values of the growth factor, epidermal growth
factor, at different times in pregnancy. A month before a child is born, the level of the growth factor doubles, probably accounting
for the burst in lung development that normally happens in the month before birth. In babies born prematurely, this last burst of
lung development fails to occur, and they must be kept on mechanical ventilation for weeks at a time, at great expense.

About GenoMed

GenoMed`s mission is to improve patient outcomes using Next Generation Disease Management(TM).

For more information, please contact GenoMed`s Chief Medical Officer, Dr. David Moskowitz, tel. [phone], fax,
928-395-2580, email: [e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed`s treatments, its
research and development approach and business model, and the suggestion that lung immaturity in the newborn might be
improved with epidermal growth factor. The words or phrases "would be," "may," "possible," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results
could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) whether our treatment approach succeeds; (b) whether we will have sufficient financing and
collaboration to conduct our research and development; and (c) our research and development`s being subject to economic,
regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should
not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and
specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments,
unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: Dr. David Moskowitz, Chief Medical Officer, of GenoMed, Inc.,
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed Seeks Collaborators to Avoid Dialysis in Acute Kidney Failure

ST. LOUIS, Jan 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based biotechnology company, announced today that it is seeking collaborators in a trial to
treat acute kidney failure with an intravenous drug, rather than with the kidney machine. This trial is for patients with new,
sudden loss of kidney function, not for chronic dialysis patients.

In pilot data, the drug regimen avoided the need for dialysis in over 80% of adults in the hospital with acute kidney failure. This
drug regimen has also been used with similar success for newborns with acute kidney failure in the Neonatal Intensive Care
Unit. The same treatment should be useful in preventing immediate shutdown of kidney transplants.

Patients are given a loading dose and an infusion of an already existing medication, aminophylline. On August 8, 2001,
Genomed filed its first application for worldwide patent protection involving aminophylline in acute kidney failure.

"Despite the introduction of kidney dialysis within the past 50 years," said Dr, Moskowitz, GenoMed`s Chief Medical Officer,
"acute kidney failure still carries a 50% mortality rate. It is extremely expensive for all concerned. Avoiding dialysis may be the
first step towards reducing the costs and mortality of acute kidney failure. This treatment should be especially useful in settings
without ready access to kidney dialysis machines, such as third-world hospitals or disaster sites like earthquakes."

About GenoMed

GenoMed`s mission is to improve patient outcomes using Next Generation Disease Management(TM).

For more information, please contact GenoMed`s Chief Medical Officer, Dr. David Moskowitz, tel. [phone], fax,
928-395-2580, email: [e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed`s treatments, its
research and development approach and business model, and the suggestion that acute kidney failure can be treated with
aminophylline. The words or phrases "ought to," "may," "possible" or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) whether our treatment approach can indeed avoid kidney dialysis; (b) whether we will have
sufficient financing and collaboration to conduct our research and development; and (c) our research and development`s being
subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this
press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not
undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences,
developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: Dr. David Moskowitz, Chief Medical Officer, of GenoMed, Inc.,
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed Seeks Nursing Home Volunteers for Anti-Aging Treatment

ST. LOUIS, Jan 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or
"GenoMed"), a St. Louis, Missouri-based genomics company, announced today that it is seeking elderly volunteers in nursing
homes to test a new medication in addition to their current medications.

GenoMed has discovered that an extremely safe class of drugs called ACE inhibitors may be useful for many serious diseases
of aging, including dementia, strokes, heart disease, and degenerative joint disease ("osteoarthritis"). ACE stands for
"angiotensin converting enzyme."

GenoMed found that patients with multi-infarct dementia (but not Alzheimer`s dementia), strokes, heart disease, and
osteoarthritis tend to have overactivity of their ACE enzyme. A logical approach is to inhibit ACE in the elderly so as to improve
quality of life.

The research supporting this new treatment approach was published in the Fall, 2002 in Diabetes Technology and Therapeutics.

About GenoMed

GenoMed is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause
disease.

For more information, please contact GenoMed`s Chief Medical Officer, Dr. David Moskowitz, tel. [phone], fax,
928-395-2580, email: [e-mail] or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed`s treatments, its
research and development approach and business model, and the suggestion that age-related diseases might benefit from
inhibition of ACE. The words or phrases "ought to," "may," "possible," or similar expressions are intended to identify
"forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties,
including but not limited to: (a) whether our treatment approach results in improved outcomes for nursing home patients, or
whether our treatment needs to be started earlier in a patient`s lifetime; (b) whether we will have sufficient financing to conduct
our research and development; and (c) our research and development`s being subject to economic, regulatory, governmental,
and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of
any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any
obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or
circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: Dr. David Moskowitz, Chief Medical Officer, of GenoMed, Inc.,
[phone], or fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:

GENOMED INC files Form NT 10-K, Notification of Late Filing



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

COMMISSION FILE NUMBER 000-49720
CUSIP 37243C 10 2

(Check One): [X]Form 10-KSB [_]Form 11-K [_]Form 10-QSB [_]Form N-SAR
For Period Ended: DECEMBER 31, 2002

[_] Transition Report on Form 10-K
[_] Transition Report on Form 20-F
[_] Transition Report on Form 11-K
[_] Transition Report on Form 10-Q
[_] Transition Report on Form N-SAR
For the Transition Period Ended:__________________________________________

Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates: ________________________________

PART I -- REGISTRANT INFORMATION

Full name of registrantGenoMed, Inc.

Former name if applicable

Address of principal executive office (Street and number):4560 Clayton Avenue

City, state and zip codeSt. Louis, Missouri 63110

PART II -- RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), (Paragraph 23, 047),
the following should be completed. (Check box if appropriate.)

[X] | (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[X] | (b) The subject annual report, semi-annual report, transition report on
Form 10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the 15th calendar day following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and
(Amended in Release No. 34-26589 (Paragraph 72, 435), effective April 12, 1989,
54 F.R. 10306.)
[ ] | (c) The accountant`s statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.

PART III -- NARRATIVE

State below in reasonable detail why the Form 10-K, 11-K, 20-F 10-Q, N-SAR or
the transition report portion thereof could not be filed within the prescribed
time period. (Amended in Release No. 34-26589 (Paragraph 72, 435), effective
April 12, 1989, 54 F.R. 10306.)

The Form 10-KSB could not be filed within the prescribed time because the
Registrant requires additional time in order to finalize year-end financial
information, complete consolidation of financial statements and complete
managements discussion and analysis.

PART IV -- OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Brenda Hamilton, Esquire561416-8956
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s). [X] Yes [_] No

(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[_] Yes [X] No

If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.

GenoMed, Inc.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

Date:March 27, 2003

/s/ Dr. David Moskowitz
PRESIDENT/CHIEF EXECUTIVE OFFICER/CHAIRMAN OF THE BOARD/CHIEF FINANCIAL
OFFICER/CHIEF ACCOUNTING OFFICER

[Bombenleger]

GMED -- GenoMed, Inc.
Com (1 Cent)

Company News and Press Releases From Other Sources:
GenoMed Scores Win over 7th Disease

ST. LOUIS, Mar 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Bulletin: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics company already practicing Next Generation Disease Management(TM), announced today that alopecia areata, an autoimmune disease, has responded dramatically to the Company`s patent-pending treatment approach. This raises to seven the number of diseases which have been slowed or even reversed by GenoMed`s approach, and is the second autoimmune disease to do so. The first autoimmune disease to respond was psoriasis a few months ago.

In 2002, GenoMed`s Chief Medical Officer, David Moskowitz, MD, began treating a 60-year-old white man with type II diabetes and severe psoriasis. The goal of the treatment was to achieve effective tissue ACE inhibition so as to prevent progression of the patient`s diabetes. Remarkably, the treatment also put the patient`s psoriasis into remission, so that he no longer had to take daily methotrexate (75 milligrams), a chemotherapy drug. In retrospect, this result had been predicted by GenoMed`s genomic epidemiology data [published in Diabetes Technology & Therapeutics, vol. 4, no. 5, pp. 683-711 (2002)].

Using genomic epidemiology data, GenoMed had observed that a large number of autoimmune diseases including psoriasis were associated with overactivity of the angiotensin I-converting enzyme (ACE). It would therefore be logical to treat these diseases with an ACE inhibitor, or an angiotensin II receptor blocker (ARB). Both ACE inhibitors and ARBs already exist, and have enviable safety records.

The latest dramatic response came in a second autoimmune disease, alopecia areata. In this disease, a person`s own T cells attack their hair follicles, causing patches of baldness. A 14-year-old white girl whose alopecia areata could only be controlled by steroid injections into her scalp had hair loss every day for the past two months since her last scalp injections, despite using a potent steroid cream and an anti-viral cream on her scalp at night. A ball of hair the size of a half dollar would fill her shower drain every morning. Within 36 hours of starting an ARB, her hair loss stopped. She has stopped the steroid and anti-viral creams, and is still taking the ARB, without any further hair loss. It is too early to tell how long her remission will last using this new treatment approach.

This raises to seven the number of diseases which have responded dramatically to GenoMed`s treatment approach. They include chronic kidney failure due both to diabetes and to high blood pressure, in which GenoMed`s approach actually improved kidney function if begun early enough in the disease. This means that GenoMed`s treatment could prevent 85% of dialysis in the U.S. at a savings of $15 billion if it were fully implemented.

Besides alopecia areata and psoriasis, GenoMed has individual case reports for the following serious diseases: emphysema, poor circulation, and acute kidney failure.

Dr. Moskowitz commented, "Of the seven diseases, five admittedly involve only case reports. But better patient outcomes data usually starts this way. What is impressive is that our case reports all involve patients whose disease was at a late stage, and who were failing drug treatment."

Dr. Moskowitz continued, "Our approach to autoimmune diseases is completely novel, and these diseases generally don`t respond well to current treatment. Such dramatic responses as we`ve seen so far suggest that we are attacking a very early step in the disease process."

Dr. Moskowitz ended by saying, "What`s extremely exciting is that all of these dramatic responses have been predicted by our genomic epidemiology data. With each clinical success, my confidence in our genomic data gets stronger. Our data further suggest that we ought to have similar success in over 150 common diseases, including other autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis; other T cell disorders like infection with HIV and progression to AIDS; most solid cancers as well as chronic leukemias and lymphomas; almost all cardiovascular disease; and even some psychiatric diseases like manic-depression and schizophrenia. We look forward to collaborating with more patients and their physicians to see if we`re right."

About 125 patients with multiple sclerosis (MS) have contacted the company since January, and a few have already began using the Company`s treatment. Because they have relapsing-remitting disease, it will take at least a year to know if the treatment is working. Several patients with rheumatoid arthritis and lupus have also contacted the Company. A handful of patients with metastatic pancreatic and colon cancer have been on GenoMed`s treatment since last summer.

Since GenoMed conducts its trials through a patient`s current physician, any patient with access to the Internet can volunteer to participate in GenoMed`s Clinical Outcomes Improvement Program(TM).

Click here for the Clinical trials form:
http://216.234.225.2/sendFeedBack.asp?B=571&RL=3260&S=5036

GenoMed`s business model is to prove that its patent-pending treatment approach works for a particular disease, and then to license its treatments to health insurance plans globally.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. As the only biotechnology company practicing Next Generation Disease Management(TM), its business model is to help manage patients in return for a monthly payment. The St. Louis Business Journal (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… first reported that the company had applied for patents based on its finding that overactivity of the ACE gene is associated with many common, age-related diseases. The Company has filed patent applications on its new treatments for both human and animal use.

For questions, please contact Dave Moskowitz, MD, tel. [phone], FAX [phone], email: [e-mail], or David Pollack, email: [e-mail], or visit GenoMed at www.genomedics.com.

[Bombenleger]

Company News and Press Releases From Other Sources:
GenoMed Announces Potential Therapy for SARS

ST. LOUIS, Fla., Apr 25, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today a novel anti-viral therapy that may decrease mortality in the current epidemic of SARS (severe acute respiratory syndrome). The Company is looking for patient and physician collaborators.

SARS is caused by a coronavirus. However, it is not the virus which kills people, but their own exuberant immune response. Down-modulating their immune response in a precise, not general, fashion, should convert coronavirus to just another viral infection, no more serious than the common cold.

GenoMed has case reports showing the ability of angiotensin II receptor blockers (AT1 Receptor blockers, or ARB`s) to arrest the excessive immune responses in autoimmune diseases such as alopecia areata and psoriasis. Alopecia areata is particularly instructive. In this disease, patients lose the hair from their scalp as well as the rest of their body because of an autoimmune attack on their hair follicles by their own T cells. Others have shown that helper T cells of the CD4+ variety make excessive interferon-gamma (IFN-gamma). The IFN-gamma turns off proliferation of the cells in the dermal papilla that normally become part of the growing strand of hair. The hair follicle becomes quiescent as a result of excessive IFN-gamma production.

IFN-gamma is the key cytokine (cell stimulator) in viral infections, such as coronavirus. In viral infections, CD4+ T cells recruit CD8+ cytotoxic T lymphocytes to the site of infection. The recruitment and activation of cytotoxic T cells is due in large part to secretion of IFN-gamma. IFN-gamma is also made by antigen-presenting cells like macrophages, and by the infected epithelial cells themselves.

GenoMed believes that angiotensin II stimulates CD4+ helper T cells and antigen-presenting cells, and perhaps even infected epithelial cells, to secrete more IFN-gamma. The rate-limiting enzyme for angiotensin II production is the angiotensin II-converting enzyme (ACE). ACE is expressed on the surface membrane of T cells as well as activated macrophages. Angiotensin II likely also stimulates production of other cytokines, either directly or indirectly, such as interleukin-1 and tumor necrosis factor-alpha (TNF-alpha). These last two are the pyrogens which cause the high fevers seen in SARS patients.

Angiotensin II may also be responsible for the increased vascular permeability in the lungs of SARS patients, as well as their respiratory insufficiency. Angiotensin II probably normally causes vasoconstriction of pulmonary arterioles, and directs blood away from alveoli that no longer are involved in gas exchange. Alveoli full of immune cells fighting virally infected epithelial cells are no longer good at gas exchange, since they`re essentially under water.

GenoMed has filed a patent application for the use of "sartans" for SARS. A "sartan" is a drug that specifically inhibits the angiotensin II type 1 receptor (AT1R). It appears that angiotensin II operates through the AT1 receptor to activate lymphocytes and macrophages, but that the type 2 angiotensin II receptor promotes death ("apoptosis") of these cells. Thus, an AT1 receptor blocker might be ideal for selectively turning off an overly exuberant host immune response.

A number of "sartans" are already on the market, where they are used to treat high blood pressure. They require a prescription. Examples include valsartan, irbesartan, candesartan, losartan, telmisartan, and eprosartan. Since SARS patients are dehydrated and their blood pressure is low to start with, the smallest dose of the "sartan" should be broken in half and then used once a day to avoid an excessive drop in blood pressure.

GenoMed has applied for patent protection on this approach but is now recruiting patients and physicians to collaborate in a world-wide trial of its efficacy. Participating patients and physicians will be able to license the treatment for free in exchange for agreeing to contribute their outcomes to an eventual publication.

In particular, GenoMed predicts that the patients who are the sickest SARS patients will have the ACE deletion/deletion (D/D) genotype. This genotype is associated with the highest expression of ACE on T cell membranes. It is interesting that 10% of Asians die of SARS, and 10% of Asians are ACE D/D. Other populations have a higher frequency of ACE D/D. For example, 25% of Caucasians are ACE D/D, about 32% of African Americans have the ACE D/D genotype, and 45% of Africans are ACE D/D. This suggests that SARS may become much more lethal if it spreads to non-Asian populations. (Incidentally, the high population frequency of the ACE D/D genotype could also help explain why HIV has been so successful at infecting people of African descent, and why African Americans have 8-fold more HIV-associated nephropathy than Caucasians infected with HIV).

GenoMed would also welcome the participation of any of the manufacturers of the sartans in this worldwide trial, e.g. through donation of their drug or other financial help.

If this novel approach to anti-viral therapy works, the Company`s next target will be patients with HIV and those who are at risk for HIV.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the gene pathways that cause disease. A St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases. The Company has filed worldwide patent applications on its new treatments, and is eager to license them globally. GenoMed`s research results are more fully described on its website, www.genomedics.com

For questions, please contact GenoMed at 314-977-0110, FAX [phone], email: [e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments and business model. The words or phrases "would be," "ought to," "will allow," "may," "intends to," "believe," "will likely result," "are expected to," "will continue," "is anticipated," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients with coronavirus infection and SARS respond to this treatment approach; (b) whether our genomic epidemiologic results will lead to clinical improvements in every single disease; (c) whether we will have sufficient financing to conduct our research and development; (d) how competition from existing or new competitors will impact our business, and (e) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: Dave Moskowitz, GenoMed, Inc., [phone], or fax,
[phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[CR0K0]

Ja,das ist OTC...



Croko

[morchel]

ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri- based medical genomics and Next Generation Disease Management(TM) company, announced today that it is working with Turkish medical authorities caring for victims of yesterday`s earthquake in Bingol in eastern Turkey.

The current casualty estimates are 250 dead and 1,000 injured, including 50 who will require kidney dialysis for crush injury syndrome. Crush injury syndrome, a form of rhabdomyolysis, involves muscle breakdown and acute kidney failure. Normally, dialysis is required until kidney function recovers days to weeks later. Some patients may require dialysis indefinitely, taxing the country`s ability to provide expensive medical care. Of 12 survivors brought to hospital yesterday, 7 are already on kidney dialysis.

GenoMed has applied for patent protection on the use of an existing drug, aminophylline, to restore kidney function and avoid dialysis in the setting of acute kidney failure. Its treatment has worked in adults and infants in the hospital setting, but this is the first time it will be used for earthquake victims. GenoMed has licensed its treatment to Dr. Mehmet Sukru Sever for use among Bingol earthquake victims. Dr. Sever coordinates kidney dialysis for survivors of the earthquake.

Dr. David Moskowitz, GenoMed`s Chairman and CEO, said, "We believe our treatment will work in crush injury, just as it has worked for other causes of acute kidney failure. We have seen restoration of kidney function within hours in the hospital setting. This is significant, since acute kidney failure greatly increases the risk of dying, as well as the cost of hospitalization. If we can restore kidney function rapidly in earthquake victims, they will have a better survival rate, and will be less likely to require long-term dialysis."

Dr. Moskowitz continued, "Given that school-children are still trapped in the rubble, and at increasing risk for crush injury syndrome, it is reassuring to know that our treatment has already been used safely among the most vulnerable children: infants in a Neonatal ICU."

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed`s research results are more fully described on its website, www.genomedics.com

For questions, please contact David Moskowitz MD or David Pollack at 314-977-0110, FAX [phone], email: [e-mail] or [e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments and business model. The words or phrases "would be," "ought to," "potential," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients with crush injury respond to this treatment approach, especially if they are rescued after a long time; (b) whether we will have sufficient financing to conduct our research and development; (c) how competition from existing or new competitors will impact our business, and (d) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

/CONTACT: David Moskowitz, MD, e-mail, [e-mail], or
David Pollack, e-mail, [e-mail], both of GenoMed, Inc.,
[phone], or fax, [phone]/

/Web site: http://www.genomedics.com /

FYI

morchel

[morchel]

Schau mer mal pb noch so einen Spike gibt!



morchel

[Bombenleger]

GenoMed Describes Molecular Mechanism of Diabetes

ST. LOUIS, May 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today that a research article describing the possible molecular mechanism responsible for diabetes and its complications was published today in Diabetes Technology & Therapeutics, a peer-reviewed journal.

The article is entitled "Pathophysiologic Implications of Angiotensin I- Converting Enzyme as a Mechanosensor: Diabetes." It tries to explain why angiotensin I-converting enzyme (ACE) is associated statistically with both type 1 ("juvenile onset") and type 2 ("adult onset") diabetes mellitus, and all their complications: kidney failure, blindness ("retinopathy"), and nerve damage ("neuropathy"). Having been able to prevent diabetic kidney failure, GenoMed has established that the statistical association of ACE means that ACE is involved causally.

Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "This paper speculates on the biochemical mechanism of how ACE leads not only to diabetes but to all its complications. It will require experimental confirmation in the laboratory, although clinical confirmation already exists. Meanwhile, the paper establishes a rationale for using effective tissue ACE inhibition in all diabetic patients, not just those with early kidney failure. Controlling sugar levels without fully inhibiting tissue ACE may explain why patients with diabetes still have such dismal outcomes."

There are 20 million patients in the U.S. with diabetes. The annual cost of their care exceeds $100 billion.

Dr. Moskowitz continued, "This paper explains how a hydrophobic ACE inhibitor like ramipril could actually prevent diabetes, as was found unexpectedly in the HOPE trial published in the New England Journal of Medicine in January, 2001. This paper says why our treatment approach should be extended to the 60 million Americans with high blood pressure, who are at increased risk of developing diabetes, so as to prevent their getting diabetes at all."

Dr. Moskowitz ended by saying, "Finally, what is perhaps most exciting for all `baby boomers` like me is that diabetes in many ways represents accelerated aging. This paper expands on previous papers in the same journal describing how ACE may be activated with each heartbeat. This may well be the clock whose ticking leads to fatal diseases like heart attacks and cancers. We now have a rationale for slowing the clock, and perhaps preventing most diseases of aging."

The article was published in Diabetes Technology and Therapeutics (2003), volume 5, number 2, pages 189-199.

GenoMed has applied for patents on the above material, including its novel treatment to inhibit tissue ACE maximally. GenoMed is marketing its Clinical Outcomes Improvement Progam(TM) to patients and healthcare plans in the U.S. and abroad, based on the Company`s discoveries.

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the molecular mechanism of disease. A St. Louis Business Journal article http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common, age-related diseases. How ACE starts diabetes and leads to diabetic complications is the subject of the article described here. The Company has filed patent applications on its new treatments for both human and veterinary use.

For questions, please contact David Moskowitz MD or David Pollack, 1-314-977-0115, FAX [phone], email: [e-mail] or [e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments, its research and development approach and business model, and the publication of the article "Pathophysiologic Implications of Angiotensin I-Converting Enzyme as a Mechanosensor: Diabetes." The words or phrases "would be," "ought to," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our molecular model is supported by subsequent research; (b) whether our molecular epidemiologic results will actually lead to clinical improvements; (c) whether we will have sufficient financing to conduct our research and development; (d) whether competition from existing or new competitors will impact our business, and (e) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: David Moskowitz MD, [e-mail], or David
Pollack, [e-mail], both of GenoMed, Inc., [phone], or
fax, [phone]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[Bombenleger]

GenoMed Launches Worldwide Internet-Based Trial Against SARS

ST. LOUIS, May 9, 2003 /PRNewswire-FirstCall via COMTEX/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today that it has launched a worldwide clinical trial against SARS.

SARS (severe acute respiratory syndrome) is only lethal because of the exaggerated host immune response to the novel antigens on the virus`s surface. Eventually, the human population will develop a more modulated immune response to the SARS coronavirus, and the virus` lethality will subside, just as it has for the two existing strains of human coronavirus that currently cause the common "cold."

Until then, the best way to decrease lethality of the virus is to decrease the host`s exaggerated immune response, in as safe and specific a way as possible. Steroids are not safe or specific enough. Quarantine, always disruptive socially and economically, is no longer practicable in the modern world. GenoMed has concluded that inhibition of angiotensin II is the ideal method of prophylaxis against the virus` most harmful effect, respiratory failure due to monocyte infiltration of the alveolus, the lung`s gas-exchange unit (see GenoMed`s previous press releases).

GenoMed is now accepting volunteers in its worldwide clinical trial against SARS. Click here to learn more about our clinical trial:

http://216.234.225.2/sendFeedBack.asp?B=571&RL=3260&S=5036

Volunteers will receive background information and an informed consent document. They will be instructed to contact their local physician, whose cooperation is required for participation in the study. Depending on their blood pressure, volunteers will be prescribed either a hydrophobic ACE inhibitor or an angiotensin II receptor blocker (ARB, also called "sartan") by their physician, and their clinical course will be observed by their physician. If this treatment works as expected, mortality will be reduced among volunteers relative to non-participants. As is customary with all of GenoMed`s clinical trials, volunteers who pioneer GenoMed`s treatments will receive free use of that treatment for the life of GenoMed`s patent.

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article ( http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including HIV infection, AIDS, and autoimmune diseases. The Company has filed worldwide patent applications on its new treatments, and is eager to license them globally. GenoMed`s research results are more fully described on its website, www.genomedics.com .

For questions, please contact David W. Moskowitz, MD, MA(Oxon.), FACP at 314-977-0110, FAX [phone], email: [e-mail] or visit us at www.genomedics.com.

This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments and business model. The words or phrases "would be," "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward- looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients with coronavirus infection and SARS respond to this treatment approach; (b) whether we will have sufficient financing to conduct our research and development; (c) how competition from existing or new competitors will impact our business, and (d) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

SOURCE GenoMed, Inc.

CONTACT: David W. Moskowitz, M.D., of GenoMed, Inc., [phone], or
fax, [phone], or [e-mail]

URL: http://www.genomedics.com
http://www.prnewswire.com

Copyright (C) 2003 PR Newswire. All rights reserved.

[morchel]

nach DNAP eine der interessantesten Subpennies

http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s…

morchel

[morchel]

GenoMed Recommends Preparing Now for SARS Later This Year: Focuses on Host Immune Response, Not the Virus
Monday July 14, 9:30 am ET


ST. LOUIS, July 14 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (OTC Pink Sheets: GMED - News), a St. Louis, Missouri-based Next Generation Disease Management(TM) company, reaffirmed today its unconventional but practical approach to deadly viruses such as SARS, West Nile virus, and HIV.
ADVERTISEMENT


Dr. David Moskowitz, GenoMed`s Chairman and Chief Medical Officer, said, "Most epidemiologists think SARS will come back later this year. Some say SARS could be as bad as the influenza pandemic of 1918. The problem is that it will be at least a decade before anyone has a vaccine or a safe drug to use against the virus. Quarantining the world until then doesn`t make much sense to me."

Dr. Moskowitz continued, "Although unconventional, our approach is practical in that it is ready now, it`s safe, and it`s easily testable. We`ve taken a close look at the pathology of SARS, as well as West Nile virus. Like SARS, the West Nile virus has already been killing people, and it will be a long time before we have a vaccine or an effective anti-viral drug. In both diseases, the people who have died have had an exaggerated immune response to the virus. This runs counter to conventional wisdom, which holds that the elderly victims of SARS and West Nile virus are immunosuppressed. We would say instead that the elderly victims of these viruses were immuno-imbalanced, and that the suppressor arm of their immune response was under-active. They didn`t die of too little immune activity, but of too much. This is an unconventional view of geriatric immunology."

Dr. Moskowitz added, "To add to our unorthodoxy, we`ve discovered that blocking angiotensin II can gently suppress the immune response. It must be a safe way to suppress the immune response, since ACE inhibitors and angiotensin II receptor blockers (ARBs) have been used by hundreds of millions of patients for the past 25 years, and there hasn`t been a single case report of someone dying from being overly immunosuppressed on one of these drugs. From the public health point of view, I would see no problem recommending population-wide prophylaxis against SARS with an ARB if the ARB worked in our clinical trials."

ACE (angiotensin I-converting enzyme), which produces angiotensin II from angiotensin I, appears on the surface membrane of macrophages and T lymphocytes when they become activated. Angiotensin II is an under-appreciated activator of these cells. Macrophages and T cells are the body`s first-line defense against a viral infection, and make up the body`s innate immune response, a very ancient system. The innate immune response appears to determine whether a patient lives or dies. If it over-reacts, the patient does poorly.

Dr. Moskowitz summarized by saying, "Our approach to viral disease is unorthodox but practical. Everyone else is focused on killing the virus or vaccinating against it, while we`re focusing on the host response, because that`s what we can manipulate safely right now. Virologists tend to think a host`s immune response can never be strong enough, and that the virus is what`s killing patients. We think the opposite: that people are dying because their immune response is too strong. This is not a subtle disagreement. The autopsy results for SARS, West Nile virus, and polio, though, are completely on our side."

Dr. Moskowitz ended by saying, "If we`re right, our treatment approach should work against more than the SARS virus. It ought to work against West Nile virus, and even against HIV. Our treatment approach could be a big help in President Bush`s fight against AIDS. ACE inhibitors and ARBs are inexpensive enough to be used by any developing country. It only remains to show that our approach works. For that we need patient volunteers. We`re actively pursuing such clinical trials."

GenoMed`s approach to gently diminish the host`s immune response can be used where no antiviral therapy or vaccine yet exists, as for SARS and West Nile virus. It can also complement antiviral therapy which may be toxic or unaffordable, as in HIV. It could conceivably be used to cover individuals who failed to be vaccinated during an acute virus outbreak, as in polio. In polio, the more active the host`s immune response to the virus, the more damage was done to the patient`s motor neurons, and the more extensive the subsequent paralysis.

Pathology reveals that, in serious viral diseases, the worst complications appear to be caused by an over-exuberant immune response, rather than by the virus itself. T cells are involved primarily in West Nile virus, and macrophages in SARS. HIV involves both cell types. HIV first reproduces in activated macrophages for several months, before switching to activated T cells within the same person. Diminishing the ability of macrophages and T cells to become activated, by blocking the action of angiotensin II, ought to decrease the ability of the HIV virus to reproduce itself. It should also delay the progression to full-blown AIDS. Many complications of AIDS, like Kaposi`s sarcoma and HIV-associated kidney failure, appear to result from the reproduction of activated macrophages.

GenoMed is now accepting volunteers interested in trying to prevent serious viral infections. Click here to learn more about our clinical trials: http://www.b2i.us/sendFeedBack.asp?B=571&RL=3260&S=5036 .

Volunteers will be instructed to contact their local physician, whose cooperation is required for participation in the study. Depending on their blood pressure, volunteers will be prescribed either an ACE inhibitor or an angiotensin II receptor blocker (ARB) by their physician, and their clinical course will be observed closely by their physician. If this treatment approach works as expected, severity of disease will be reduced among volunteers relative to non-participants.

As is customary with all of GenoMed`s clinical trials, volunteers who pioneer GenoMed`s treatments will receive free use of that treatment for the life of GenoMed`s patent.

About GenoMed

GenoMed, Inc. is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the molecular pathways that cause disease. A St. Louis Business Journal article ( http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/1… ) first reported that the company has applied for patents based on its finding that the ACE gene is associated with a very large number of common diseases including HIV infection, AIDS, and autoimmune diseases. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed`s research results are more fully described on its website, www.genomedics.com .

For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0110, FAX [phone], email: [e-mail] or visit us at www.genomedics.com .

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.`s (the Company`s) treatments and business model. The words or phrases "would be," "ought to," "should," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether patients exposed to the SARS coronavirus, West Nile virus, HIV, and polio will respond favorably to this novel treatment approach; (b) whether we will have sufficient financing to conduct our research and development; (c) how competition from existing or new competitors will impact our business, and (d) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we do not undertake, and specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


morchel